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Abstract 
 
There is a large body of research supporting the importance of market orientation in 
determining performance.  A growing body of research supports the notion that strategic alliance 
management competencies positively influence performance.  Few empirical investigations have 
examined the importance of market orientation in the biotechnology industry, much less the 
effect of alliance orientation on performance, or the combined effect of market and alliance 
orientation on performance.  This study explores these relationships among Canadian 
biotechnology companies with medical/healthcare focuses.  Of the 394 Canadian 
medical/healthcare biotechnology companies identified, 81 usable responses were received, 
yielding a response rate of 20.6 percent. 
It was found that market orientation positively and significantly influenced business 
performance, supporting the first hypothesis.  Additionally, alliance orientation positively and 
significantly influenced business performance, supporting the second hypothesis.  However, 
when market and alliance orientation were examined together, alliance orientation’s effect on 
business performance remained positive and significant, but market orientation’s effect on 
business performance became negative and non-significant.  This prompted a further analysis 
that investigated the presence of a mediation relationship.  Market orientation was fully mediated 
by alliance orientation in its relationship with business performance. 
This study contributes academically by adding to market and alliance orientation research 
and by the successful development of a biotechnology-specific performance instrument.  This 
study contributes to marketing and management strategy, as it outlines performance indicators 
that enable high performance. 
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1 
CHAPTER 1 
INTRODUCTION 
Biotechnology is “the application of science and technology to living organisms, as well 
as parts, products, and models thereof, to alter living or nonliving materials for the production of 
knowledge, goods, and services” (Organisation for Economic Co-operation and Development 
2011).  The North American Industry Classification System (2007) provides a similar definition 
of the biotechnology industry, emphasizing the industry’s use of research and development 
(R&D) in the areas of microorganisms and genetic alteration to discover new processes, 
prototypes, and products for various sectors (North American Industry Classification System 
2007).  In its entirety, the biotechnology industry “consists of the development, manufacturing, 
and marketing of products based on advanced biotechnology research” (Datamonitor 2011d).  
Due to the increase of cross-border financing, technology, alliances, and mergers and 
acquisitions, biotechnology is a rapidly expanding worldwide industry (Datamonitor 2011d; 
Simon and Kotler 2003). 
1.1 Biotechnology Market 
In 2010 the global biotechnology market value was estimated to be 250 billion USD and 
projected to grow to 300 billion USD by 2015 (Datamonitor 2011d).  The largest subsector of the 
global biotechnology market is medical/healthcare, accounting for more than 67 percent of total 
market value (Datamonitor 2011d).  The biotechnology industry in the Americas (North and 
South America) accounts for over 46 percent of the global market (Datamonitor 2011d).  
Specifically, the United States (US) is the world-leader in biotechnology (Datamonitor 2011a).  
Similar to the US, Canada is a leader in biotechnology, ranking in the top five countries globally 
(Conference Board of Canada 2005; Government of Canada 2011; Industry Canada 2011b).  In 
2010 and in the midst of global economic turmoil, the Canadian biotechnology industry 
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experienced an increase in the signing of licensing agreements, attainment of capital raised 
privately and through equity markets, and engagement in mega-mergers and acquisitions, 
demonstrating the industry’s resilience (Ernst & Young 2011).  Today, it is estimated that 
Canada has over 500 private biotechnology companies with at least one product in development 
(Conference Board of Canada 2005; Industry Canada 2011b; BIOTECanada 2011a).  There are 
many subsectors in the biotechnology industry including medical/healthcare, agriculture/food, 
environmental/industrial, and information technology services (Industry Canada 2011b; 
Datamonitor 2011b).  As with the global biotechnology market, the medical/healthcare subsector 
dominates the Canadian industry (Industry Canada 2011b; Datamonitor 2011b).  Estimates 
suggest anywhere from 60 to 66 percent of all Canadian biotechnology companies are 
medical/healthcare firms (Datamonitor 2011d; Conference Board of Canada 2005; Industry 
Canada 2011b).  Additionally, the majority of these companies are small- to medium-sized 
enterprises (SMEs) (Conference Board of Canada 2005; Datamonitor 2011b; Rajamaki 2008). 
1.2 Biotechnology Managerial Skills 
Renko, Carsrud, Brannback, and Jalkanen (2005) state that some managers of 
technology-focused SMEs tend to overemphasize the importance of science and technology and 
neglect managerial issues including marketing and product positioning in the marketplace 
(Renko et al. 2005).  In the biotechnology market, effectiveness is predicated on having a strong 
and complete management team with competencies in all functional areas including marketing 
(Woiceshyn 1993).  Costa, Fontes, and Heitor (2004) state that marketing is an imperative 
managerial competency for successful biotechnology commercialization.  Additionally, 
biotechnology ventures with high market knowledge are more likely to be acquisition candidates, 
obtain licensing deals, and accumulate capital infusions (Renko, Carsrud, and Brannback 2008).  
Contrarily, managerial deficiencies such as the lack of marketing expertise can lead to obstacles 
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in the biotechnology development process (Rajamaki 2008; Costa, Fontes, and Heitor 2004; 
Eriksson and Rajamaki 2010).  Chief Executive Officers (CEOs) and managers of biotechnology 
companies identified having a focus in marketing strategy and the establishment of strategic 
alliances as critical industry success factors (Hourd and Williams 2008).  Yim and Weston 
(2007) found that there is a strong demand for biotechnology managers and entrepreneurs with 
marketing and alliance-building competencies, as these traits enable organizational success.  Due 
to the industry’s competitive intensity with regard to the attainment of capital and survival, 
biotechnology managers need to be successful in identifying target markets and sharing 
knowledge with strategic alliance partners as these competencies have been proven to perpetuate 
organizational success (Terziovski and Morgan 2006). 
1.2.1 Market Orientation 
Marketing is defined as “the activity, set of institutions, and processes for creating, 
communicating, delivering, and exchanging offerings that have value for customers, clients, 
partners, and society at large” (American Marketing Association 2007).  In marketing and 
management academic research, market orientation (MO) is fundamental to the marketing 
concept (Appiah-Adu 1998; Appiah-Adu and Ranchhod 1998; Drucker 1954; Farrell and 
Oczkowski 1997; Greenley 1995; Han, Kim, and Srivastava 1998; Harris 2001; Kohli and 
Jaworski 1990; McCarty 1960; Narver and Slater 1990; Subramanian and Gopalakrishna 2001).  
Conceptualizations provided by Narver and Slater (1990) and Kohli and Jaworski (1990) are the 
two most widely employed measures for investigating MO.  Narver and Slater (1990) theorize 
that MO is a construct comprised of behavioural components including customer orientation, 
competitor orientation, and interfunctional coordination (Narver and Slater 1990; Farrell 2002).  
Kohli and Jaworski (1990) postulate that MO is an organizational activity aimed at generating 
market knowledge, disseminating knowledge throughout the organization, and incorporating 
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knowledge in order to better serve customers.  Regardless of the measure used to assess MO, 
scoring high on either scale signifies organizational commitment to marketing strategy.  For the 
purpose of this study, the Narver and Slater (1990) definition of MO will be adopted. 
Utilizing the Hourd and Williams (2008) and Yim and Weston (2007) findings as a basis 
for further investigation, a MO instrument could be used to measure the employment of 
marketing strategy in biotechnology companies.  Although strategic marketing capabilities are 
said to be an imperative in the commercialization process, the body of research surrounding 
marketing and biotechnology is limited, especially regarding MO in the biotechnology industry. 
1.2.2 Alliance Orientation 
Strategic alliances are inter-organizational agreements aimed at collectively achieving 
individual organizational goals and gaining competitive advantages (Elmuti, Abebe, and Nicolosi 
2005; Parkhe 1993; Varadarajan and Cunningham 1995).  In the pharmaceutical and 
biotechnology industries, strategic alliances are highly prevalent as these cooperative efforts 
enable global expansion and minimize risk for alliance partners (Simon and Kotler 2003; 
McCutchen and Swamidass 2004).  Alliance orientation (AO) is an instrument used to measure 
the employment of alliance strategies in organizations (Kandermir, Yaprak, and Cavusgil 2006).  
However, unlike previous strategic alliance measurements, AO aims to comprehensively 
measure strategic alliance practices.  Kandermir, Yaprak, and Cavusgil (2006) developed the AO 
instrument to measure a company’s ability to scan for new alliance partners, coordinate alliance 
strategies, and learn from alliance experiences.  Similar to MO, scoring high on the AO scale 
indicates organizational commitment to activities pertaining to alliance strategy.  Despite the 
importance of strategic alliances and the AO instrument’s ability to measure strategic alliance 
management comprehensively, no known study has employed the AO instrument in the 
biotechnology industry. 
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1.3 Marketing, Strategic Alliances, and Performance 
As discussed, marketing and strategic alliances in the field of biotechnology are critical 
industry success factors (Hourd and Williams 2008; Yim and Weston 2007).  With the use of 
MO instruments, Appiah-Adu and Ranchhod (1998), De Luca, Verona, and Vicari (2010), and 
Renko, Carsrud, and Brannback (2009), investigated the relationship between biotechnology 
companies’ commitment to marketing and its influence on performance.  Additional studies have 
examined the relationship between strategic alliance metrics (e.g. size, efficiency, horizontal, 
vertical, proactiveness) (Baum, Calabrese, and Silverman 2000; Baum and Silverman 2004; 
Forest and Martin 1992; George et al. 2001; George, Zahra, and Wood 2002; Levitte and Bagchi-
Sen 2010; Silverman and Baum 2002; Stuart, Ozdemir, and Ding 2007).  However, none have 
employed the AO instrument to holistically measure the relationship between strategic alliances 
and performance.   
To date, no known study explores MO, AO, and performance in the Canadian 
biotechnology industry.  Exploring the relationship between MO, AO, and performance in the 
Canadian biotechnology industry is valuable for many reasons.  Namely, Canada is a global 
leader in biotechnology, investigating antecedents to performance has theoretical and managerial 
implications, MO, AO, and performance in the Canadian biotechnology context is an unstudied 
area, and MO and AO are measures that assess two key critical industry success factors (e.g. 
marketing and strategic alliances). 
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CHAPTER 2 
LITERATURE REVIEW 
Business performance is a recurrent theme for management researchers and practitioners 
(Venkatraman and Ramanujam 1986).  Investigating possible antecedents (e.g. MO and AO) to 
business performance bridges the gap between management theory and practice, as results often 
prove to have practical implications for managers to improve performance. 
2.1 Market Orientation and Performance 
The MO and performance relationship has been studied across various industries 
(biotechnology, construction/surveyor, exporters, forestry, hotel, internet advertisers, 
manufacturing, mass-merchandisers, multi-industry, and services), in many countries (Australia, 
Canada, China, Ghana, India, Israel, Saudi Arabia, United Kingdom, and United States), with 
differing MO instruments, and using contrasting performance measurements (Appiah-Adu 1998; 
Appiah-Adu and Ranchhod 1998; Greenley 1995; Harris 2001; Narver and Slater 1990; 
Subramanian and Gopalakrishna 2001; Cadogan, Cui, and Li 2003; Cadogan, Diamantopoulos, 
and Siguaw 2002; Dawes 2000; Deng and Dart 1994; Diamantopoulos and Hart 1993; Jaworski 
and Kohli 1993; Kara, Spillan, and DeShields 2005; Matsuno and Mentzer 2000; Noble, Sinha, 
and Kumar 2002; Perry and Shao 2002; Pulendran, Speed, and Widing 2000; Rose and Shoham 
2002; Sargeant and Mohamad 1999; Slater and Narver 1994; Tay and Morgan 2002; Bhuian 
1998).  Despite the diverse settings, MO has been repeatedly shown to have a positive, and direct 
or moderating role in its relationship with performance (Appiah-Adu 1998; Appiah-Adu and 
Ranchhod 1998; Greenley 1995; Harris 2001; Narver and Slater 1990; Subramanian and 
Gopalakrishna 2001; Cadogan, Cui, and Li 2003; Cadogan, Diamantopoulos, and Siguaw 2002; 
Dawes 2000; Deng and Dart 1994; Jaworski and Kohli 1993; Kara, Spillan, and DeShields 2005; 
Matsuno and Mentzer 2000; Noble, Sinha, and Kumar 2002; Perry and Shao 2002; Pulendran, 
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Speed, and Widing 2000; Rose and Shoham 2002; Slater and Narver 1994; Tay and Morgan 
2002; Bhuian 1998).  Few studies, including a United Kingdom (UK) multi-industry and a UK 
hotel study, showed that MO had no effect, or a very weak effect, on performance 
(Diamantopoulos and Hart 1993; Sargeant and Mohamad 1999).  The majority of studies used 
data from the manufacturing industry or a multitude of sectors (De Luca, Verona, and Vicari 
2010; Heslop and Qu 2007), while only a small number of studies have explored MO and 
performance in the biotechnology industry (Appiah-Adu and Ranchhod 1998; De Luca, Verona, 
and Vicari 2010; Renko, Carsrud, and Brannback 2009). 
Appiah-Adu and Ranchhod (1998) employed the Narver and Slater (1990) instrument to 
measure MO and performance among UK biotechnology companies.  Biotechnology executives 
from various subsectors self-administered mailed questionnaires (Appiah-Adu and Ranchhod 
1998).  Appiah-Adu and Ranchhod (1998) hypothesized that MO would be positively related to 
new product success, growth in market share, profit margins, and overall performance.  Their 
findings supported three of four hypotheses, specifically MO’s positive relationship with growth 
in market share, profit margins, and overall performance (Appiah-Adu and Ranchhod 1998).  No 
statistically significant relationship was found between MO and new product success (Appiah-
Adu and Ranchhod 1998).  Appiah-Adu and Ranchhod (1998) concluded that the unsupported 
hypothesis was a result of the peculiarities of the biotechnology industry.  Specifically, Appiah-
Adu and Ranchhod (1998) stated that variables other than MO may be more influential in new 
product success (e.g. successful clinical trials).   
Similarly, De Luca, Verona, and Vicari (2010) adapted the Narver and Slater (1990) 
instrument to measure MO in the biotechnology industry.  The authors designed new 
performance measures, developed from in-depth interviews with Italian biotechnology 
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executives.  De Luca, Verona, and Vicari (2010) hypothesized that customer orientation, 
competitor orientation, and interfunctional coordination would be positively related to their 
newly developed performance construct.  As with Appiah-Adu and Ranchhod (1998), De Luca, 
Verona, and Vicari (2010) mailed questionnaires to executives in varying subsectors of the 
biotechnology industry.  Results supported their third hypothesis, indicating interfunctional 
coordination was positively and directly related to performance (De Luca, Verona, and Vicari 
2010).  It was found that customer orientation and competitor orientation were not positively and 
directly related to performance, leading to the rejection of the first and second hypotheses. When 
knowledge integration as a moderating variable was introduced, customer orientation showed a 
positive and significant contribution to performance but the competitor orientation and 
performance relationship was unchanged (De Luca, Verona, and Vicari 2010). 
Renko, Carsrud, and Brannback (2009) adapted the Kohli and Jaworski (1990) scale to 
explore the relationship between MO and performance.  Capital invested in the company was the 
main measure of performance and was adjusted based on firm size (Renko, Carsrud, and 
Brannback 2009).  Renko, Carsrud, and Brannback (2009) hypothesized that biotechnology 
ventures’ MO is positively associated with capital infusions.  A structured questionnaire was 
administered in-person to CEOs or Managing Directors of human health biotechnology 
companies in the US, Finland, and Sweden.  Human health biotechnology companies were 
defined as those that operated in the areas of human therapeutics, diagnostics, medical devices, 
and technologies.  Overall, MO was found to be an antecedent to capital invested in 
biotechnology companies, ultimately supporting their hypothesis.  However, when examined 
separately, the significance of the MO and performance relationship was only present among 
Finnish and Swedish companies.  This suggests that differences, related to the strength of the 
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relationship between MO and performance, may exist across various national borders.  Renko, 
Carsrud, and Brannback’s (2009) findings suggest that it may be fruitful to examine the MO and 
performance relationship in different countries (e.g. Canada).   
To date, no known study of biotechnology companies has examined the MO and 
performance relationship in the Canadian context.  The Canadian biotechnology market is 
similar to Finland, Sweden, and the US, as these countries’ industries are medical/healthcare-
focused and dominated by SMEs (Datamonitor 2011a; Datamonitor 2011b; Datamonitor 2011c).  
The Canadian biotechnology industry more closely resembles the Scandinavian as opposed to the 
American market with respect to the market size, number of companies, and supporting 
industries (Datamonitor 2011a; Conference Board of Canada 2005; Industry Canada 2011b; 
Ernst & Young 2011; BIOTECanada 2011a; Datamonitor 2011b; Datamonitor 2011c; 
Biotechnology Europe 2012b; Biotechnology Europe 2012a; Canada’s Venture Capital & Private 
Equity Association 2012; Battelle Technology Partnership Practice 2010; Datamonitor 2012a; 
Datamonitor 2012b; Datamonitor 2011e).  In the US, the biotechnology market is valued at 84.8 
billion USD, it headquarters over 1,700 biotechnology companies and more than 4,000 venture 
capital (VC) firms, and is the global leader in pharmaceuticals with a market value of 265 billion 
USD (Datamonitor 2011a; Ernst & Young 2011; Battelle Technology Partnership Practice 2010; 
Datamonitor 2011e).  Contrarily, the Canadian, Finnish, and Swedish biotechnology markets are 
substantially smaller in value than their American counterpart (Datamonitor 2011b; Datamonitor 
2011c).  Similar to Canada’s estimated 500-plus biotechnology companies, together, Sweden and 
Finland have just over 550 firms (Conference Board of Canada 2005; Industry Canada 2011b; 
BIOTECanada 2011a; Biotechnology Europe 2012b; Biotechnology Europe 2012a).  
Additionally, compared to the VC industry in the US, the Canadian, Finnish, and Swedish VC 
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markets are less established in terms of the number of companies and overall experience 
(Biotechnology Europe 2012b; Biotechnology Europe 2012a; Canada’s Venture Capital & 
Private Equity Association 2012).  Finally, compared to Canada and Sweden the US 
pharmaceutical industry is over 10 and 40 times larger respectively (Datamonitor 2011a; 
Datamonitor 2012a; Datamonitor 2012b).  Based on the market similarities involving Canada, 
Finland, and Sweden, it is theorized that the MO and performance relationship in Canada will 
resemble the Finnish and Swedish results as opposed to the American results from the Renko, 
Carsrud, and Brannback (2009) study.  Therefore, the foregoing discussion regarding MO and 
performance and the comparison of biotechnology markets led to the formulation of the first 
hypothesis.  
Hypothesis 1:  Market orientation has a positive and significant effect on business 
performance 
2.2 Strategic Alliances and Performance 
Strategic alliances in the North American biotechnology industry have been extensively 
studied in academic research (Baum, Calabrese, and Silverman 2000; Baum and Silverman 2004; 
Forest and Martin 1992; George et al. 2001; George, Zahra, and Wood 2002; Silverman and 
Baum 2002; Sarkar, Echambadi, and Harrison 2001; Standing, Standing, and Lin 2008).  
Furthermore, Baum, Calabrese, and Silverman (2000), Baum and Silverman (2004), and 
Silverman and Baum (2002) examined elements of strategic alliances in all subsectors of the 
Canadian biotechnology industry.  In various settings involving biotechnology companies, 
individual strategic alliance elements have been empirically shown to have positive and direct 
relationships with performance (Baum, Calabrese, and Silverman 2000; Baum and Silverman 
2004; Forest and Martin 1992; George et al. 2001; Sarkar, Echambadi, and Harrison 2001). 
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From 1991 through 1996, Baum, Calabrese, and Silverman (2000) studied strategic 
alliances and performances of new Canadian biotechnology companies.  They found that new 
biotechnology companies’ performance increased with the size and efficiency of the alliance 
networks (Baum, Calabrese, and Silverman 2000).  Particularly, biotechnology companies that 
obtained early alliances with pharmaceutical companies experienced more patenting, a 
proliferation of revenue, an increase in the number of R&D and non-R&D employees, and 
growth in R&D spending (Baum, Calabrese, and Silverman 2000). 
Baum and Silverman (2004) investigated differing types of strategic alliances and their 
relationship with financing and overall performance in the Canadian biotechnology industry.  
Strategic alliances were categorized as either horizontal or vertical.  Horizontal alliances were 
defined as partnerships or agreements with rival biotechnology companies (Baum and Silverman 
2004).  Vertical alliances were further classified as either upstream or downstream agreements 
(Baum and Silverman 2004).  Upstream alliances were agreements between biotechnology 
companies and “universities, research institutes, government labs, hospitals, or industry 
associations” (Baum and Silverman 2004, 422).  Downstream alliances were defined as 
partnerships with firms closer to the market, including pharmaceutical, chemical, or marketing 
companies (Baum and Silverman 2004).  Baum and Silverman (2004) found that new 
biotechnology ventures financially benefited most from downstream and horizontal alliances.  
Baum and Silverman (2004) suggest that biotechnology companies with alliances closer to the 
market (downstream or horizontal) raise more capital and perform well because it demonstrates 
legitimacy and commercial viability to VCs.  
George, Zahra, Wheatley, and Khan (2001) also studied alliance types versus 
performance among biotechnology companies.  Alliance types included horizontal, vertical, 
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knowledge generative, and knowledge attractive.  Knowledge generative alliances pertained to 
partnerships or agreements involving joint R&D, and knowledge attractive alliances involved 
licensing or purchasing agreements (George et al. 2001).  These results coincide with Baum and 
Silverman (2004), promoting the idea that alliances vertically downstream and closer to the 
market (licensing and purchasing agreements) increase the performances of biotechnology 
companies. 
Sarkar, Echambadi, and Harrison (2001) explored the relationship between alliance 
proactiveness and market performance.  Sarkar, Echambadi, and Harrison (2001) define alliance 
proactiveness as scanning the business environment for alliance opportunities and engaging in 
proactive activities to obtain alliances.  Responses from executives in the US biotechnology 
industry enabled Sarkar, Echambadi, and Harrison (2001) to conclude that alliance proactiveness 
affects performance, and that the relationship is stronger with smaller biotechnology companies. 
Contrarily, Forrest and Martin (1992) found that both small and large biotechnology 
companies in Canada experienced a wide array of, and arguably equally positive, outcomes from 
strategic alliances.  Forrest and Martin (1992) caution that although small and large 
biotechnology companies benefited from strategic alliances, positive results did not come 
without considerable time and energy. 
There is collective evidence showcasing how effective strategic alliance management is 
an antecedent to performance (Baum, Calabrese, and Silverman 2000; Baum and Silverman 
2004; Forest and Martin 1992; George et al. 2001; Sarkar, Echambadi, and Harrison 2001).  
Based on the above findings, strategic alliance management requires the establishment of the 
right partnerships and agreements and the distinction between upstream, downstream, knowledge 
generative, and knowledge attractive alliances (Baum, Calabrese, and Silverman 2000; Baum 
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and Silverman 2004; George et al. 2001).  Managers of biotechnology companies must also 
practice proactive alliance activities and devote time and energy to existing alliances in order to 
increase the likelihood of commercial success (Forest and Martin 1992; Sarkar, Echambadi, and 
Harrison 2001). 
The Kandermir, Yaprak, and Cavusgil (2006) AO instrument incorporates many alliance 
metrics found in the works of Baum, Calabrese, and Silverman (2000), Baum and Silverman 
(2004), George, Zahra, Wheatley, and Khan (2001), Forrest and Martin (1992), and Sarkar, 
Echambadi, and Harrison (2001), as it measures environmental scanning (similar to 
proactiveness), alliance coordination (effective management of partnerships at differing levels of 
development), and alliance learning (commitment to alliances).  Moreover, Simon and 
Francoise’s (2003) four key elements of structuring alliance management include items that 
resemble alliance scanning (need assessments and opportunity analyses), alliance coordination 
(alliance objectives and alliance structuring), and alliance learning (priorities and knowledge 
integration), further supporting Kandermir, Yaprak, and Cavusgil’s (2006) AO constructs.   
To date, few empirical investigations have employed the Kandermir, Yaprak, and 
Cavusgil (2006) instrument to explore AO, emphasizing this project’s ability to generate 
knowledge in an unexplored area of study.  Also, no known research explores the AO and 
performance relationship in the biotechnology industry.  Additionally, no known study has 
looked at the AO and performance relationship exclusively in one country (e.g. Canada) or in 
one biotechnology subsector (e.g. medical/healthcare).  The prior review of literature regarding 
strategic alliances and performance led to the formulation of the second hypothesis. 
Hypothesis 2:  Alliance orientation has a positive and significant effect on business 
performance  
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2.3 Market Orientation, Alliance Orientation, and Business Performance 
Marketing and strategic alliance management competencies have been cited as 
biotechnology industry success factors (Hourd and Williams 2008; Yim and Weston 2007), MO 
has been shown to increase the likelihood of commercial success in the biotechnology industry 
(Appiah-Adu and Ranchhod 1998; De Luca, Verona, and Vicari 2010; Renko, Carsrud, and 
Brannback 2009), and effective strategic alliance management has been proven to increase 
biotechnology companies’ performance (Baum, Calabrese, and Silverman 2000; Baum and 
Silverman 2004; Forest and Martin 1992; George et al. 2001; Sarkar, Echambadi, and Harrison 
2001).  Therefore, if biotechnology companies’ marketing (measured by MO) and strategic 
alliance management competencies (measured by AO) are strong and positive, performance is 
also likely to be favourable.  Empirically, MO and other constructs (e.g. organizational 
entrepreneurship, corporate entrepreneurship, organizational flexibility, export market 
knowledge, quality and service, cultural affinity, and channel support) have been identified as 
unique and additive predictors of performance (Bhuian and Habib 2004; Barrett and Weinstein 
1998; Thirkell and Dau 1998).  Combining MO and AO to examine their additive effect on 
business performance is novel, as it is presumably an unstudied research area.  The third 
hypothesis was developed based on evidence highlighting the importance of MO and strategic 
alliance management in the biotechnology industry, as well as findings from studies that 
examined MO and other constructs’ additive effect on performance. 
Hypothesis 3:  Market and alliance orientation has a positive and significant additive 
effect on business performance 
2.4 Purpose of Study 
The purpose of this study is to test the unexplored relationship between MO, AO, and 
performance in the medical/healthcare subsector of the Canadian biotechnology industry.  The 
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value of the study comes from determining if MO and AO individually and collectively are 
antecedents to business performance.  Understanding the antecedents to commercial success has 
implications for many stakeholders. 
2.5 Implications of Study 
This study has implications for managers of biotechnology companies, angel investors 
financing biotechnology start-ups, venture capitalists funding biotechnology companies, 
pharmaceutical companies looking to partner with or acquire biotechnology ventures, 
universities supporting the biotechnology industry, the Federal Government of Canada, 
Provincial Governments of Canada, Canadian economy, biotechnology industry associations, 
hospitals, medical professionals, and most importantly, patients.  Ultimately, a better 
comprehension of the antecedents to success, whether or not it is MO or AO, will have the 
potential to guide effective resource allocation and investment decisions, increase biotechnology 
commercialization success rates, stimulate the Canadian economy, and improve healthcare.  In 
addition to the societal and economic benefits, this study contributes academically by 
undertaking an industry and subsector specific exploration of MO, AO, and business 
performance.  Thereby, the study expands the scope of biotechnology marketing and strategic 
alliance management research and knowledge. 
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CHAPTER 3 
METHODOLOGY 
3.1 Study Design 
The study design was a mail and web-based survey.  Dillman’s (1978) Total Design 
Method, a set of procedures and selectively timed mailings, was adapted and employed as it has 
been shown to increase postal responses (SAGE Research Methods 2011).  Dillman’s (1978) 
procedures include printing questionnaires on standard letterhead and enclosing them in standard 
envelopes, personalizing letters and content, and timing separate mailings (Dillman 1978).  Due 
to cultural changes toward self-administration (Dillman 2000) and the increased use and 
acceptance of the Internet (Dillman 2000), a web-based option was included.  This study utilized 
a multi-modal approach to survey executives to better understand the current business practices 
of medical/healthcare biotechnology companies in Canada.  
Biotechnology executives (CEOs, Presidents, Vice Presidents, or Managing Directors) 
were identified using the Canadian Life Sciences Database and Industry Canada’s Company 
Database.  Senior executives of Canadian biotechnology companies were selected as key 
informants due to their comprehensive knowledge of company activities (e.g. marketing, alliance 
strategy, and business performance).  A multi-modal design was chosen as it allows for 
respondent choice, autonomy, and flexibility (Dillman 2000).  Interviews were considered, but 
due to the objectives and financial constraints of the project, a mail and web-based survey was 
deemed more appropriate.   
3.2 Sample 
The Canadian Life Sciences Database and Industry Canada’s Company Directory were 
used to generate a mailing list of Canadian medical/healthcare biotechnology companies.  The 
Canadian Life Sciences Database was chosen because it is available at no cost and is relatively 
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comprehensive (Canadian Life Sciences Database 2012).  The Canadian Life Sciences Database 
and Industry Canada’s Company Directory generated company profiles that included a business’ 
name, brief description, subsector, senior executive contact (CEO, President, Vice President, or 
Managing Director), address, founding year, products in clinical phases, and stock information 
(if a publicly traded company) (Canadian Life Sciences Database 2012; Industry Canada 2012).  
However, despite their similarities, Industry Canada’s Company Database produced fewer results 
and did not include information on companies’ products in development stages (Industry Canada 
2012).   
Medical/healthcare firms were defined as biotechnology or biopharmaceutical companies 
with focuses in therapeutics/diagnostics, human R&D services, cosmetic, nutraceutical, or 
veterinary areas.  Over the past few decades the activities of cosmetic, nutraceutical, 
biotechnology, and pharmaceutical companies have converged (Simon and Kotler 2003), 
emphasizing the necessity for this study’s inclusion of all companies currently operating, or with 
the potential to operate, in human health areas.  Using the Canadian Life Sciences Database, the 
aforementioned criteria was employed by filtering biotechnology companies to include only 
those in the categories of therapeutics/diagnostics, R&D services, cosmetic, nutraceutical, and 
veterinary.  Secondly, companies’ brief descriptions were read to confirm a medical, human 
health, biopharmaceutical, or pharmaceutical focus.  Using Industry Canada’s Company 
Database, the study’s criteria were fulfilled by filtering results to include 
“medical/biotechnology/chemical” companies, followed by reading companies’ of brief 
descriptions to confirm focuses in the medical, human health, biopharmaceutical, and 
pharmaceutical fields.   
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The Canadian Life Sciences Database assisted in the identification of 427 
medical/healthcare biotechnology companies.  Industry Canada’s Company Database was 
consulted in order to cross-reference findings from the Canadian Life Sciences Database.  
Industry Canada’s Company Database generated a total of 137 medical/healthcare biotechnology 
companies, demonstrating that the Canadian Life Sciences Database’s was more comprehensive.  
Despite generating fewer results, Industry Canada’s Company Database was used to identify 26 
medical/healthcare biotechnology companies that were not included in the Canadian Life 
Sciences Database.  These additional 26 medical/healthcare biotechnology companies were 
added to the existing list of 427 companies.  The final list totaled 453 medical/healthcare 
biotechnology companies.  
3.3 Questionnaire Development 
The questionnaire was five pages in length and it was estimated that the completion time 
would be ten to fifteen minutes for each respondent.  The questionnaire was comprised of five 
sections including a qualifying question, the adapted Narver and Slater (1990) MO instrument, 
Kandermir, Yaprak, and Cavusgil (2006) AO instrument, adapted and broadened De Luca, 
Verona, and Vicari (2010) R&D effectiveness instrument, and general descriptive questions.  In 
order to ensure the inclusion of biotechnology companies located in the Province of Quebec, 
with the cooperation of the Université du Québec à Montréal (UQAM), the original 
questionnaire was translated from English (Appendix A) to French (Appendix B).  As a result, 
the questionnaire cover pages included both the University of Saskatchewan and the UQAM 
logos.   
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3.3.1 Qualifying Question 
The qualifying question was used to confirm that companies had a medical/healthcare 
focus.  This item was designed to safeguard against including responses from non-
medical/healthcare companies.   
3.3.2 Market Orientation Instrument 
The Narver and Slater (1990) MO instrument has been found to be superior to the 
instrument developed by Kohli and Jaworski (1990) (Farrell and Oczkowski 1997; Matsuno and 
Mentzer 2000; Cano, Carrillat, and Jaramillo 2004; Gauzente 1999; Pelham 1993).  Statistically, 
Narver and Slater’s (1990) achieved greater reliability (α = 0.88) than Kohli and Jaworski’s 
(1990) (α = 0.71) MO instrument (Farrell and Oczkowski 1997; Narver and Slater 1990).  
Furthermore, it has been concluded that the validity of Kohli and Jaworski’s (1990) MO 
construct is only moderately supported (Kohli, Jaworski, and Kumar 1993).  Conceptually, the 
Narver and Slater (1990) scale better equates MO to a business’ performance, as it captures the 
element of serving the needs of its customers (Cano, Carrillat, and Jaramillo 2004; Gauzente 
1999).  Furthermore, the Kohli and Jaworski (1990) MO instrument neglects to deal with 
external factors (e.g. competitor orientation), only focusing on information generation (Cano, 
Carrillat, and Jaramillo 2004).  Gauzente (1999) asserts that the Narver and Slater (1990) 
instrument better measures current commitment to MO and the vocabulary used is much richer.  
Therefore, based on its conceptual and statistical superiority, only the Narver and Slater (1990) 
scale was used to measure MO and the instrument was modified specifically for the 
biotechnology industry. 
Appiah-Adu and Ranchhod (1998) modified the Narver and Slater (1990) MO instrument 
for use in the biotechnology industry.  In order to better suit the biotechnology industry, a total of 
three questions were eliminated and two questions were reworded.  Subsequent to Appiah-Adu 
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and Ranchhod’s (1998) modifications, coefficient alpha scores were obtained and demonstrated 
acceptable reliabilities (α > 0.70).  Due to its proven and successful application in the 
biotechnology industry, the Appiah-Adu and Ranchhod (1998) adapted version of Narver and 
Slater’s (1990) MO instrument was utilized (Appendix C).  For scale-size congruency with other 
instruments, the MO instrument was collapsed from a seven- to a five-point Likert scale, as the 
AO instrument cannot be expanded from a five- to a seven-point scale. 
 3.3.3 Alliance Orientation Instrument 
As discussed, the Kandemir, Yaprak, and Cavusgil (2006) AO instrument measures 
alliance scanning, coordination, and learning.  Alliance scanning is the first component of AO 
and it measures a firm’s ability to identify new partners, gather new information about existing 
alliances, and engage in newly emerging alliance opportunities (Kandermir, Yaprak, and 
Cavusgil 2006).  Sarkar, Echambadi, and Harrison (2001) emphasized the importance of alliance 
scanning as they found alliance proactiveness perpetuated performance.  Alliance coordination 
involves managing various activities across differing alliances, employing appropriate strategies 
with partners, and transferring knowledge to alliance members.  Baum, Calabrese, and Silverman 
(2000), Baum and Silverman (2004), and George, Zahra, Wheatley, and Khan (2001) discuss the 
complexities and importance of alliance management, legitimizing Kandemir, Yaprak, and 
Cavusgil’s (2006) second component of alliance coordination.  Alliance learning is the final 
component of Kandemir, Yaprak, and Cavusgil’s (2006) AO instrument.  Alliance learning 
measures the experiences and learning processes of alliance members.  Forrest and Martin (1992) 
indirectly support Kandemir, Yaprak, and Cavusgil’s (2006) alliance learning component by 
stressing the importance of effort and commitment in alliance relationships.  Conceptually, the 
Kandemir, Yaprak, and Cavusgil (2006) AO instrument is appropriate for the biotechnology 
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industry because its components are supported by previous industry-related research regarding 
strategic alliances and performance.   
Empirical work utilizing the Kandemir, Yaprak, and Cavusgil (2006) AO instrument is 
fairly limited.  Kandemir, Yaprak, and Cavusgil (2006) used the instrument to explore AO and 
performance among technology companies.  Technology companies from the chemical, 
manufacturing, electronic, and computer industries were selected for their study.  A total of 182 
usable responses were obtained in order to test their hypotheses.  Kandemir, Yaprak, and 
Cavusgil’s (2006) findings showed that AO is positively and directly related to alliance 
performance and indirectly related, through alliance performance as a moderator, to market 
performance.  
Sarkar, Aulakh, and Madhok (2004) leveraged two of the developed components, namely 
alliance scanning and alliance coordination, when they explored their relationship with alliance 
capital.  Unlike Kandemir, Yaprak, and Cavusgil (2006), the research was conducted with multi-
industry respondents and the components were used individually to test hypotheses.  Findings 
showed a positive direct relationship between alliance scanning and alliance capital, and alliance 
coordination and alliance capital.   
Kandemir, Yaprak, and Cavusgil (2006) and Sarkar, Aulakh, and Madhok (2004) 
obtained acceptable reliability, demonstrating construct rigor collectively and independently.  
Furthermore, the measures prove to be successful measuring different performance constructs.  
Therefore, the original five-point Kandemir, Yaprak, and Cavusgil (2006) AO instrument 
(Appendix D) was employed to explore the relationship with business performance in Canada’s 
medical/healthcare biotechnology industry. 
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3.3.4 Business Performance Instrument 
In MO and strategic alliance research, performance has been measured objectively, 
subjectively, and with differing instruments.  Frequently, performance measurements have 
included return-on-investment, return-on-assets, new product success, profitability, and sales 
revenue (Appiah-Adu 1998; Greenley 1995; Han, Kim, and Srivastava 1998; Harris 2001; Zhang 
2009).  Commonly, performance elements have been measured subjectively, by asking 
respondents to rate company performance relative to its competitors (Appiah-Adu 1998; 
Greenley 1995; Harris 2001; Zhang 2009; Lukas and Ferrell 2000).  The works of Dess and 
Robinson (1984), Robinson and Pearce (1988), and Venkatraman and Ramanujam (1986) have 
been cited as justification for the use of subjective measures.  Specifically, they found strong 
correlations between subjective responses and objective measures of firm performance 
(Venkatraman and Ramanujam 1986; Dess and Robinson 1984; Robinson and Pearce 1988).  
The use of a subjective performance measure is also supported when access to objective 
performance data is limited.  As many Canadian biotechnology companies are SMEs or not 
publicly traded, it is necessary to employ subjective performance measures (Conference Board of 
Canada 2005; Datamonitor 2011b; Rajamaki 2008; Canadian Life Sciences Database 2012).  
Appiah-Adu and Ranchhod (1998) expressed their concerns related to the difficulty of 
obtaining objective performance data in the biotechnology industry.  In the Appiah-Adu and 
Ranchhod (1998) study of UK biotechnology companies, respondents rated company 
performance relative to competitors’ new product success, growth in market share, profit 
margins, and overall performance.  De Luca, Verona, and Vicari (2010), support Appiah-Adu 
and Ranchhod’s (1998) justification for their use of subjective performance measurements in the 
biotechnology industry.  However, De Luca, Verona, and Vicari (2010) stress the need for 
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redefining and using industry specific measures of performance when studying biotechnology 
companies.   
Performance measurements related to patents, products, capital raised, milestones met, 
networks and alliances, mergers and acquisitions, and licensing agreements have been used and 
suggested as more appropriate measures of biotechnology performance (Baum, Calabrese, and 
Silverman 2000; George et al. 2001; George, Zahra, and Wood 2002; De Luca, Verona, and 
Vicari 2010; Renko, Carsrud, and Brannback 2009; Sarkar, Echambadi, and Harrison 2001; 
Cumby and Conrod 2001; Folta, Cooper, and Baik 2006; Lazzarotti, Manzini, and Mari 2011; 
Stuart and Sorenson 2003).  De Luca, Verona, and Vicari’s (2010) R&D effectiveness scale 
captures many of the mentioned elements desired for a biotechnology performance construct 
(Appendix E).  For this study, the De Luca, Verona, and Vicari (2010) instrument was adapted to 
include items related to capital, alliances and partnerships, and milestones, broadening the 
construct to capture overall biotechnology performance (PERF) (Appendix F).  For consistency 
with the other instruments (MO and AO), the newly constructed PERF instrument was a five-
point Likert scale. 
3.3.5 Descriptive Items 
Descriptive items allowed for a comparison of the companies’ locations, science park 
affiliations or non-affiliations, association memberships (e.g. BIOTECanada), ownership 
structures (e.g. publicly traded), executives’ educational backgrounds (e.g. MBA), founding 
years, and number of employees.   
3.3.5.1 Descriptive items one, two, and three 
The first three descriptive items identify companies’ locations, science park affiliations, 
and biotechnology association memberships.  These items were included because in certain 
settings, positive externalities and economic benefits originate from geographically clustering 
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around, and knowledge sharing with, other technology-intensive companies (Efendioglu 2005).  
In a study of the US biotechnology industry, companies that geographically clustered 
experienced economies of agglomeration, enhanced their ability to attract alliance partners, 
obtained private equity, and innovated through partnering (Folta, Cooper, and Baik 2006).  
However, Folta, Cooper, and Baik (2006) found that economies of agglomeration provided 
economic benefits for companies only up to a certain cluster size.  Specifically, when clusters of 
biotechnology companies became too large, diseconomies of agglomeration occurred (Folta, 
Cooper, and Baik 2006). 
Descriptive items two and three were used as independent variables when analyzing their 
importance, or lack of importance, in determining MO, AO, and PERF (dependent variables) in 
the Canadian medical/healthcare biotechnology industry.  The three descriptive items were used 
with the other items to generate a profile of Canadian biotechnology companies. 
3.3.5.2 Descriptive item four 
The fourth descriptive item was included to determine companies’ ownership types. 
Differences in ownership structures have been shown to influence biotechnology companies’ 
corporate strategies and performance (Baum, Calabrese, and Silverman 2000; Stuart, Hoang, and 
Hybels 1999; Zahra 1996).  In a study of American biotechnology companies, it was found that 
R&D, patenting, and technology management strategies differed based on ownership types 
(Zahra 1996).  Zahra (1996) found that independently owned biotechnology ventures 
outperformed corporate-sponsored biotechnology ventures on a variety of metrics.  Stuart (1999) 
showed that biotechnology companies that had established partners, issued stock more quickly 
and had higher valuations than companies without such partners.  An analysis of young Canadian 
biotechnology companies demonstrated how differing ownership types and alliances led to 
dissimilar focuses, specializations, and performance (Baum, Calabrese, and Silverman 2000). 
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Descriptive item four was used as an independent variable to analyze its importance, or 
lack of importance, in determining MO, AO, and PERF (dependent variables) in the Canadian 
medical/healthcare biotechnology industry.  The fourth descriptive item was also used with the 
other items to generate a profile of Canadian biotechnology companies 
3.3.5.3 Descriptive item five 
The fifth descriptive item was included to determine CEOs’ educational backgrounds.  
There is much debate over the importance of the educational backgrounds of biotechnology 
CEOs.  Kermani and Gittins (2004) discuss how joint natural science and business educational 
programs can increase the managerial talents of biotechnology executives.  They concluded by 
recommending that biotechnology executives with educational backgrounds in natural science or 
engineering should be exposed to formal business training (Kermani and Gittins 2004).  
McMillan (2005) highlights that many biotechnology companies’ executives are PhD natural 
scientists and may lack experience in bringing products to the market and reaching profitability.  
In McMillan’s (2005) study of US publicly traded biotechnology companies, firms headed by 
CEOs with natural science PhDs had lower market valuations than firms headed by CEOs with 
other educational backgrounds.  Yet, companies led by CEOs with natural science PhDs tended 
to produce “higher-impact” patents than companies led by CEOs with other educational 
backgrounds (McMillan and Thomas 2005).  McMillan (2005) concluded that stock markets 
favour companies that are led by professional managers and the market does not base market 
valuations solely on science or technology.  Contrary to McMillan’s (2005) findings, in a study 
of American and European biotechnology companies, educations of CEOs played no role in the 
financial performance of their companies (Patzelt 2010).  
The fifth descriptive item was used with the other items to generate a profile of Canadian 
biotechnology companies.  More importantly, descriptive item five was used as an independent 
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variable to analyze its importance, or lack of importance, in determining MO, AO, and PERF 
(dependent variables) in the Canadian medical/healthcare biotechnology industry. 
3.3.5.4 Descriptive items six and seven 
Descriptive item six was designed to collect information on companies’ founding years.  
McMillan (2005) found that US stock markets favoured older and more established 
biotechnology enterprises.  Descriptive item seven was designed to collect information on 
companies’ number of employees.  In Canada, most biotechnology companies are SMEs 
(Conference Board of Canada 2005; Datamonitor 2011b; Rajamaki 2008; Government of 
Canada 2012; BIOTECanada 2011b).  Woiceshyn and Hartel (1996) compared small, medium, 
and large Canadian biotechnology companies’ performance using subjective sales measures.  It 
was found sales performance increased with company size (Woiceshyn and Hartel 1996).  
Although these findings suggest that companies that are older and have more employees 
outperform companies that are smaller and have fewer employees, both studies only measured 
performance financially.   
Descriptive items six and seven were used as independent variables to analyze their 
importance, or lack of importance, in determining overall biotechnology performance (PERF), 
MO, and AO.  Descriptive items six and seven were also used with the other items to generate a 
profile of Canadian biotechnology companies. 
3.4 Questionnaire Distribution and Data Collection 
On May 28, 2012, the first mailing of the questionnaire was sent to the 453 identified 
medical/healthcare biotechnology companies in Canada.  Each package included a cover letter 
(Appendices G & H), the questionnaire (Appendices A & B), and a paid-postage return 
envelope.  The cover letters were personally addressed to a senior executive, written on 
University of Saskatchewan letterhead, and included the link to the online questionnaire 
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(https://survey.qualtrics.com/SE/?SID=SV_5hFkveDPwEF0HxW).  The questionnaires were 
printed on green paper in order to attract attention and contrast other documents.  Two weeks 
after the first mailing, reminder postcards (Appendices I & J) were sent to executives that had 
not yet responded.  The reminder postcards were printed on green cardstock paper and included 
the link to the online questionnaire.  Two weeks following the mailing of the reminder postcard, 
the second mailing of the questionnaire was sent to those who had not responded.  The contents 
of the second mailing of the questionnaire were similar to the initial mailing, as it included a 
cover letter (Appendices K & L), the questionnaire, and a paid-postage return envelope.  Seeing 
as the survey was conducted over the summer months, data collection was extended.  Data 
collection officially concluded on August 31, 2012. 
Table 3.1  Data Collection Timeline 
Date Activity 
May 28, 2012 First wave of questionnaires mailed 
June 11, 2012 Reminder postcard mailed 
June 25, 2012 Second wave of questionnaires mailed 
August 31, 2012 Data collection concluded 
 
3.5 Data Analyses 
Data analyses were accomplished with the use of Statistical Package for the Social 
Sciences (SPSS© Version 20.0 for Mac OS).  The response rate was tabulated, demographic and 
instrument results were generated, reliability analyses were performed, factor analyses were 
conducted, the presence of a non-response bias was examined, discriminant validity was tested, 
analyses of the descriptive items were performed, and hypotheses were investigated. 
Demographic results were used to generate a profile of Canadian medical/healthcare 
biotechnology companies.  The instrument results allowed for a quantitative description of the 
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data, particularly the way respondents answered questions related to their companies’ MO, AO, 
and PERF. 
The internal reliability of the MO, AO, and PERF instruments were conducted using 
reliability analyses.  Alpha coefficients greater than 0.70 but less than 0.80 were acceptable, 
greater than 0.80 but less than 0.90 were good, and scores higher than 0.90 were excellent 
(George and Mallery 2009).  Due to the extensive use of Narver and Slater’s (1990) MO 
instrument and the advanced practices of MO research, higher Cronbach’s alpha coefficients 
could be expected.  However, for exploratory work in new areas of research (e.g. Canadian 
medical/healthcare biotechnology industry) a coefficient of 0.70 is cited as an acceptable 
measure of a construct’s internal reliability (Nunnally 1978).  Therefore, despite the extensive 
use of Narver and Slater’s (1990) MO instrument, this study’s goal was to obtain internal 
reliabilities that met or exceeded coefficients of 0.70.  Using the MO instrument in the Canadian 
medical/healthcare biotechnology industry is an unexplored research area, demonstrating the 
appropriateness for the stipulated Cronbach’s alpha coefficient (α = 0.70).  Due to limited 
research using the Kandemir, Yaprak, and Cavusgil (2006) and the De Luca, Verona, and Vicari 
(2010) instruments, obtaining a Cronbach’s alpha coefficient of 0.70 or better was also 
appropriate and justified (Nunnally 1978).   
“Factor analysis is conducted to discover what latent variables (factors) are behind a set 
of variables or measures” (SAGE Research Methods 2012a).  Factor analyses were conducted on 
MO, AO, and PERF in order to test the dimensionality of the constructs.     
Kwak and Radler (2002) found that response rates and the respondents themselves (e.g. 
Internet users and non-users) differed based on data collection formats (e.g. mail and web-based) 
(Kwak and Radler 2002).  Therefore, mail and online responses were analyzed and compared to 
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determine if any statistically significant differences existed among respondent groups.  Due to 
the financial constraints of the research project, the mailing of a non-responder questionnaire was 
not undertaken.  According to Armstrong and Overton (1977), subjects that respond later, as 
opposed to earlier, more closely resemble non-responders.  Therefore, in the absence of non-
responder questionnaires, key constructs can be compared among early and late responses to 
determine the existence of a non-response bias (Armstrong and Overton 1977).  In lieu of a non-
responder questionnaire, key constructs (MO, AO, and PERF) were compared among early and 
late responders to determine the potential existence of a non-response bias. 
Discriminant validity tests if a measure or construct is unrelated to other measures or 
constructs (Carless 2012).  “Correlation coefficients between measures of a construct and 
measures of conceptually different constructs are usually given as evidence of discriminant 
validity” (Carless 2012).  If correlation coefficients are high it demonstrates a lack of 
discriminant validity and if correlation coefficients are low or moderate it demonstrates 
discriminant validity (Carless 2012).  According to Kline (2005), if a construct’s 90 percent 
confidence interval does not contain the number one, discriminant validity has been achieved 
(Kline 2005).  The discriminant validity of MO and AO was tested in order to determine if the 
constructs measured different phenomena.  
Descriptive analyses were conducted using the descriptive data as independent variables 
and the three major constructs as dependent variables (MO, AO, and PERF).  The additional 
analyses were designed to confirm or refute previous findings related to the importance of 
clustering, ownership structures, educational backgrounds of CEOs, and company ages and sizes 
in the biotechnology industry. 
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The set of hypotheses explored the relationship between biotechnology companies’ MO 
and PERF (H1), AO and PERF (H2), and MO, AO, and PERF (H3) (Appendix M).  Using linear 
regression, hypothesis testing was accomplished using the unweighted means of constructs, 
employing listwise deletion as the method to treat missing data.  Listwise deletion was used 
because the sample had limited missing data and it has been cited as preferable to many other 
methods (Allison 2002).  Independent variables were MO and AO, and the dependent variable 
was PERF.  According to G*Power’s (1996) a priori multiple linear regression, employing 
Cohen’s (1988) minimum power requirement (1-β = 0.80) and standard error probability (α = 
0.05), a sample size of 68 was required in order to detect a medium-sized effect (ƒ2 = 0.15) of 
two predictor independent variables (MO and AO) on a dependent variable (PERF) (Erdfelder, 
Faul, and Buchner 1996; Cohen 1988).  Although it is hypothesized that MO and AO would be 
significant predictors of PERF, a medium-sized effect (ƒ2 = 0.15) was theorized because it is 
likely that there are other possible variables influencing business performance. 
If MO had a statistically significant influence on PERF (H1) and AO had a statistically 
significant influence on PERF (H2), but either MO or AO became non-significant when 
examined together (H3), a mediation relationship may have existed (Baron and Kenny 1986).  In 
order to confirm or refute the existence of a mediation relationship, a final mediation regression 
analysis was performed.  This regression analysis used the third hypothesis’ non-significant 
predictor as independent variable and its statistically significant predictor as the dependent 
variable (Baron and Kenny 1986).  If the relationship was positive and statistically significant, a 
mediation relationship existed (Baron and Kenny 1986).   
3.6 Ethical Considerations 
On April 4, 2012 a research ethics application was submitted to the University of 
Saskatchewan Behavioural Research Ethics Board.  The research project was deemed exempt 
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(BEH 12-104) from the ethics review process on April 9, 2012.  The exemption was granted due 
to the project’s focus on business practices as opposed to human behaviour.   
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CHAPTER 4 
RESULTS 
4.1 Response Rate 
Two weeks after the initial mailing, 13 responses and seven return-to-sender packages 
were received.  Therefore, 433 reminder postcards were sent to companies that had not yet 
responded.  Between the mailing of the reminder postcards and the second wave of 
questionnaires, 39 responses and 27 return-to-sender packages were received.  Four weeks after 
the initial packages were posted, the second mailing of the questionnaires were sent to the 367 
companies that had not yet responded.  From the second mailing of the questionnaires to the end 
of data collection, 35 responses and 19 return-to-sender packages were received.   
At the end of data collection a total of 87 responses and 53 return-to-sender packages 
were received.  Six of the 87 responses explicitly stated that the focus of the biotechnology 
company was not, nor did it have the potential to become, medical/healthcare focused.  These six 
were then removed, reducing the number of usable responses and sample size to 81 and 447 
respectively.  Upon receiving the return-to-sender packages, online searches were conducted in 
order to determine the status of the companies.  From the searches it was found that the 
companies had merged, been acquired, filed for bankruptcy, suspended trading, moved, or 
dissolved.  These 53 companies were subsequently removed from the sample, further reducing 
its size to 394.  Therefore, the response rate of the project was 20.6% (81/394). 
4.2 Demographic Results 
The following sections explore the demographic results including the response language, 
method of completion, company location, number of association memberships, company 
ownership structure, executive educational background, company founding year, and company 
size. 
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4.2.1 Response Language   
Companies located in Quebec received cover letters, questionnaires, and reminder 
postcards written in French.  Companies located in all other provinces received cover letters, 
questionnaires, and reminder postcards written in English.  One company, located in Quebec, 
requested that an English-version of the questionnaire be electronically mailed for its 
completion.  Out of the 81 responses, 67 (82.7%) were completed in English and 14 (17.3%) 
were completed in French.  The percentage of responses from Quebec companies (14/81, 17.3%) 
was slightly less than the percentage of French questionnaires mailed to companies in Quebec 
(101/394, 25.6%).    
4.2.2 Method of Completion 
Executives were provided mail and web-based completion options.  The number of mail 
and online responses were 61 (75.3%) and 20 (24.7%) respectively.   
4.2.3 Company Location 
The first question related to companies’ locations asked respondents if their company was 
headquartered in Canada.  Seventy-four companies (91.4%) were, and six (7.4%) were not, 
headquartered in Canada.  Of the six companies not headquartered in Canada, three were 
Canadian subsidiaries (e.g. Biotechnology Enterprise Canada).  Although these six companies 
were not headquartered in Canada, they had Canadian addresses and operated within the country.  
Due to the fact that all companies operated within Canada, all 81 responses were included. 
In order to determine approximate locations (e.g. city and province) of companies, 
respondents were asked to give the first three characters of their postal codes.  Four major 
response-based clusters were identified, including Lower Mainland, Edmonton, Toronto, and 
Montreal/Laval (Appendix N).  Table 4.1 displays the companies in each province as compared 
to the responses from province.  The majority of responses were received from Ontario (32.1%), 
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British Columbia (25.9%), and Quebec (18.5%).  It is important to note that the number of 
responses from companies located in Quebec differs from the number of French responses.  This 
incongruence was due to the Quebec-based company asking for an English version of the 
questionnaire, thereby being included as a Quebec, but not a French, response.  
Table 4.1  Provincial Responses and Companies 
Province Companies  
N (%) 
Responses  
N (%) 
British Columbia 85 (21.6) 21 (25.9) 
Alberta 29 (7.4) 12 (14.8) 
Saskatchewan 4 (1) 1 (1.2) 
Manitoba 8 (2) 1 (1.2) 
Ontario 152 (38.6) 26 (32.1) 
Quebec 100 (25.4) 15 (18.5) 
New Brunswick 3 (0.8) 0 (0) 
Prince Edward Island 3 (0.8) 2 (2.5) 
Nova Scotia 9 (2.3) 3 (3.7) 
Newfoundland and Labrador 1 (0.3) 0 (0) 
Total 394 (100)  81 (100) 
 
The third location question asked respondents if their company was located in a 
biotechnology or science park.  Twenty-seven companies (33.3%) were, and 53 companies 
(65.4%) were not, located in a biotechnology or science park.  
4.2.4 Association Memberships 
In the questionnaire, executives were asked to check all of the pharmaceutical and 
biotechnology associations for which their company held memberships.  Of the 81 companies 
that responded, 64 (79%) held at least one pharmaceutical or biotechnology association 
membership.  Membership categories ranged from zero to four or more pharmaceutical or 
biotechnology association memberships.  Table 4.2 displays responses by number of 
memberships. 
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Table 4.2  Association Memberships 
Number of memberships Responses 
N  (%) 
0 17 (21.0) 
1 25  (30.9) 
2 16  (19.7) 
3 16  (19.7) 
≥ 4 7  (8.6) 
Total 81  (100) 
 
4.2.5 Ownership Structure 
Originally, ownership structures were classified into five categories including privately 
owned, publicly traded, subsidiary, government, and other.  The government category was 
omitted, as no respondent classified its organization as a government enterprise.  The other 
category was omitted and replaced with non-profit, because the only company in the other 
category was a non-profit organization.  Table 4.3 presents responses by ownership type.  
Table 4.3  Ownership Structure 
Ownership Responses 
N  (%) 
Privately owned 61  (75.3) 
Publicly traded 13  (16.0) 
Subsidiary 4  (4.9) 
Non-Profit 1  (1.2) 
Missing data 2  (2.5) 
Total 81  (100) 
 
4.2.6 CEO’s Education 
Respondents were asked to state their CEO or President’s educational background.  
Responses varied greatly from specific degrees and majors (e.g. MBA in Finance) to simply 
areas of study (e.g. business).  Educational backgrounds were subsequently classified into seven 
categories including arts, business, doctoral, engineering, medical, science, and hybrid.  The 
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hybrid category was created as many executives (16%) were dually trained in science and 
business or law.  Seeing as the questionnaires were disseminated to the senior executives listed in 
the Canadian Life Sciences Database and Industry Canada’s Company Database, not all contacts 
were the CEO or President.  Four respondents (4.9%) indicated that they did not know the CEO 
or President’s educational background.  In these cases, an unknown was explicitly different than 
a missing response.  Table 4.4 outlines responses by CEO or President’s educational 
backgrounds.  
Table 4.4  CEO or President’s Education 
Education Responses 
N  (%) 
Arts (BA) 4  (4.9) 
Business (BComm, MBA) 8  (9.9) 
Doctoral (PhD) 33  (40.7) 
Engineering (PEng, MEng) 3  (3.7) 
Medical (MD) 7  (8.6) 
Science (BSc, MSc) 7  (8.6) 
Hybrid (MBA & PhD) 13  (16.0) 
Unknown 4  (4.9) 
Missing data 2  (2.5) 
Total 81 (100) 
 
4.2.7 Company Age 
The mean, median, and mode ages of the companies were 12.7, 10.5, and 6 years 
respectively.  Companies were grouped in five-year increments based on their founding years, 
beginning with companies founded prior to 1985 to ones founded after 2011 (Table 4.5).  The 
majority of companies were founded between 1996 and 2010. 
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Table 4.5  Founding Year 
Founding year Responses 
N  (%) 
Prior to 1985 7  (8.6) 
1986 – 1990 7  (8.6) 
1991 – 1995 8  (9.9) 
1996 – 2000 15  (18.5) 
2001 – 2005 15  (18.5) 
2006 – 2010 26  (32.1) 
2011 or after 2  (2.5) 
Missing data 1  (1.2) 
Total 81  (100) 
 
4.2.8 Company Size 
According to Industry Canada (2011), organizational size categories are micro (1 to 4 
employees), small (5 to 99 employees), medium (100 to 499 employees), and large (≥ 500 
employees) (Industry Canada 2011a).  Based on the defined categories, the majority of responses 
were from small (71.6%) companies.  Table 4.6 displays responses by Industry Canada’s 
employment size categories. 
Table 4.6  Company Size 
Employment size category 
(Number of employees) 
Responses 
N  (%) 
Micro  (1 – 4) 13  (16.0) 
Small  (5 – 99) 59  (72.8) 
Medium  (100 – 499) 4  (4.9) 
Large  (≥ 500) 3  (3.7) 
Missing data 2  (2.5) 
Total 81  (100) 
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4.3 Instrument Results 
4.3.1 Market Orientation 
As previously discussed (3.3.2 Market Orientation Instrument), the 12-item adapted MO 
instrument (Appendix C) was utilized for this study.  Responses to items four, six, seven, and 
nine were weighted toward to a moderate extent/to a considerable extent (Table 4.7).  Responses 
to the remaining items were weighted toward to a considerable extent/to a great extent (Table 
4.7).  Of the 81 responses, the mean, median, mode, and standard deviation was 3.81, 3.92, 3.75, 
and 0.71 respectively. 
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Table 4.7  Market Orientation 
  
To no 
extent 
N  (%) 
 
To a small 
extent 
N  (%) 
To a 
moderate 
extent 
N  (%) 
To a 
considerable 
extent 
N  (%) 
 
To a great 
extent 
N  (%) 
 
 
Total 
N  (%) 
(1) Our business objectives are 
driven primarily by customer 
satisfaction 
7 
(8.6) 
7 
(8.6) 
9 
(11.1) 
19 
(23.5) 
38 
(46.9) 
80 
(98.8) 
(2) Our strategy for competitive 
advantage is based on our 
understanding of customers’ 
needs 
3 
(3.7) 
1 
(1.2) 
9 
(11.1) 
26 
(32.1) 
41 
(50.6) 
80 
(98.8) 
(3) Our business strategies are 
driven by our beliefs about how 
we can create greater value for 
customers 
2 
(2.5) 
2 
(2.5) 
7 
(8.6) 
20 
(24.7) 
49 
(60.5) 
80 
(98.8) 
(4) We measure customer 
satisfaction systematically and 
frequently 
16 
(19.8) 
9 
(11.1) 
23 
(28.4) 
20 
(24.7) 
12 
(14.8) 
80 
(98.8) 
(5) All business functions share 
information concerning 
competitors’ strategies 
3 
(3.7) 
10 
(12.3) 
16 
(19.8) 
28 
(34.6) 
23 
(28.4) 
80 
(98.8) 
(6) We rapidly respond to 
competitive actions that 
threaten us 
3 
(3.7) 
7 
(8.6) 
25 
(30.9) 
28 
(34.6) 
17 
(21) 
80 
(98.8) 
(7) Top managers regularly 
discuss competitors’ strengths 
and strategies 
2 
(2.5) 
6 
(7.4) 
22 
(27.2) 
35 
(43.2) 
16 
(19.8) 
81 
(100) 
(8) We target customers where 
we have an opportunity for 
competitive advantage 
1 
(1.2) 
3 
(3.7) 
7 
(8.6) 
32 
(39.5) 
37 
(45.7) 
80 
(98.8) 
(9) We freely communicate 
information about our success 
and unsuccessful customer 
experiences across all business 
functions 
10 
(12.3) 
5 
(6.2) 
24 
(29.6) 
25 
(30.9) 
17 
(21) 
81 
(100) 
(10) All business functions (e.g. 
marketing/sales, manufacturing, 
R&D, finance/accounting, etc.) 
are integrated in serving the 
needs of our target markets 
2 
(2.5) 
6 
(7.4) 
15 
(18.5) 
32 
(39.5) 
26 
(32.1) 
81 
(100) 
(11) All business functions 
understand how everyone in 
our business can contribute to 
creating customer value 
2 
(2.5) 
5 
(6.2) 
18 
(22.2) 
27 
(33.3) 
29 
(35.8) 
81 
(100) 
(12) We share resources with 
other business units 
10 
(12.3) 
5 
(6.2) 
12 
(14.8) 
33 
(40.7) 
20 
(24.7) 
80 
(98.8) 
 
 
4.3.2 Alliance Orientation 
As previously discussed (3.3.3 Alliance Orientation Instrument), the nine-item AO 
instrument (Appendix D) was utilized in this study.  Responses to items one, two, three, and nine 
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were weighted toward agree/strongly agree (Table 4.8).  Responses to the remaining items were 
weighted toward neutral/agree (Table 4.8).  Of the 80 responses, the mean, median, mode, and 
standard deviation was 3.89, 4.00, 4.00, and 0.70 respectively. 
Table 4.8  Alliance Orientation 
 Strongly 
disagree 
N  (%) 
Disagree 
N  (%) 
Neutral 
N  (%) 
Agree 
N  (%) 
Strongly 
agree 
N  (%) 
Total 
N  (%) 
(1) We actively monitor our 
environment to identify 
partnering opportunities 
0 
(0) 
3 
(3.7) 
5 
(6.2) 
32 
(39.5) 
40 
(49.4) 
80 
(98.8) 
(2) We routinely gather 
information about prospective 
partners from various forums 
(e.g. trade shows, industry 
conventions, databases, 
publications, internet, etc.) 
0 
(0) 
4 
(4.9) 
5 
(6.2) 
32 
(39.5) 
39 
(48.1) 
80 
(98.8) 
(3) We are alert to market 
developments that create 
potential alliance opportunities 
0 
(0) 
3 
(3.7) 
4 
(4.9) 
44 
(54.3) 
29 
(35.8) 
80 
(98.8) 
(4) Our activities across 
different alliances are well 
coordinated 
0 
(0) 
7 
(8.6) 
27 
(33.3) 
28 
(34.6) 
18 
(22.2) 
80 
(98.8) 
(5) We systematically 
coordinate our strategies across 
different alliances 
0 
(0) 
8 
(9.9) 
25 
(30.9) 
28 
(34.6) 
18 
(22.2) 
79 
(97.5) 
(6) We have processes to 
systematically transfer 
knowledge across alliance 
partners 
1 
(1.2) 
12 
(14.8) 
28 
(34.6) 
25 
(30.9) 
13 
(16) 
79 
(97.5) 
(7) We conduct periodic 
reviews of our alliances to 
understand what we are doing 
right and what we are doing 
wrong 
1 
(1.2) 
8 
(9.9) 
23 
(28.4) 
32 
(39.5) 
15 
(18.5) 
79 
(97.5) 
(8) We periodically collect and 
analyze field experiences from 
our alliances 
1 
(1.2) 
8 
(9.9) 
26 
(32.1) 
30 
(37) 
14 
(17.3) 
79 
(97.5) 
(9) We modify our alliance 
related procedures as we learn 
from experience 
1 
(1.2) 
6 
(7.4) 
16 
(19.8) 
39 
(48.1) 
17 
(21) 
79 
(97.5) 
 
4.3.3 Business Performance 
As previously discussed (3.3.4 Business Performance Instrument), the newly constructed 
eight-item PERF instrument (Appendix F) was utilized in this study.  Responses to item eight 
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were weighted toward to a moderate extent/to a considerable extent (Table 4.9).  The majority of 
responses to the items were weighted toward to a considerable extent/to a great extent (Table 
4.9).  Of the 79 responses, the mean, median, mode, and standard deviation was 3.76, 3.88, 4.25, 
and 0.77 respectively. 
Table 4.9  Business Performance 
  
To no 
extent 
N  (%) 
 
To a small 
extent 
N  (%) 
To a 
moderate 
extent 
N  (%) 
To a 
considerable 
extent 
N  (%) 
 
To a great 
extent 
N  (%) 
 
 
Total 
N  (%) 
(1) Generation of new 
innovative products or projects 
1 
(1.2) 
3 
(3.7) 
14 
(17.3) 
30 
(37) 
31 
(38.3) 
79 
(97.5) 
(2) New patents 14 
(17.3) 
6 
(7.4) 
12 
(14.8) 
15 
(18.5) 
31 
(38.3) 
78 
(96.3) 
(3) Quality and relevance of 
scientific output 
0 
(0) 
2 
(2.5) 
16 
(19.8) 
34 
(42) 
27 
(33.3) 
79 
(97.5) 
(4) Attainment of scientific 
results or milestones 
1 
(1.2) 
3 
(3.7) 
17 
(21) 
32 
(39.5) 
26 
(32.1) 
79 
(97.5) 
(5) Recruitment of new 
personnel with outstanding 
knowledge and skills 
4 
(4.9) 
6 
(7.4) 
17 
(21) 
32 
(39.5) 
20 
(24.7) 
79 
(97.5) 
(6) Scientific or technological 
leadership in your environment 
0 
(0) 
4 
(4.9) 
20 
(24.7) 
31 
(38.3) 
24 
(29.6) 
79 
(97.5) 
(7) Attainment of new capital, 
either public or private 
14 
(17.3) 
12 
(14.8) 
15 
(18.5) 
18 
(22.2) 
19 
(23.5) 
78 
(96.3) 
(8) Maintenance and generation 
of alliances or partnerships 
8 
(9.9) 
7 
(8.6) 
19 
(23.5) 
29 
(35.8) 
16 
(19.8) 
79 
(97.5) 
 
4.4 Analysis of Instruments 
4.4.1 Market Orientation 
According to Narver and Slater (1990), “the theory of market orientation suggests that the 
three behavioral components are equally important” (Narver and Slater 1990, 26).  As Narver 
and Slater (1990) viewed customer orientation, competitor orientation, and interfunctional 
coordination as equally important, they measured MO by using the unweighted mean score of 
the components.   
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4.4.1.1 MO reliability 
In order to evaluate the internal reliability of the MO instrument, a reliability analysis 
was undertaken.  The 12-item MO instrument’s Cronbach’s alpha was 0.876, thereby exceeding 
the previously defined requirement (α ≥ 0.70).  Table 4.10 shows how Cronbach’s alpha would 
change if any of the 12 items were deleted.     
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Table 4.10  MO Total Statistics 
  
Scale mean if 
item deleted 
Scale 
variance if 
item deleted 
 
Corrected item-
total correlation 
Squared 
multiple 
correlation 
 
Cronbach’s alpha 
if item deleted 
Our business objectives are 
driven primarily by customer 
satisfaction 
41.91 58.005 0.630 0.639 0.863 
Our strategy for competitive 
advantage is based on our 
understanding of customers’ 
needs 
41.61 62.004 0.589 0.702 0.865 
Our business strategies are 
driven by our beliefs about how 
we can create greater value for 
customers 
41.48 63.674 0.504 0.518 0.870 
We measure customer 
satisfaction systematically and 
frequently 
42.77 57.655 0.642 0.516 0.862 
All business functions share 
information concerning 
competitors’ strategies 
42.14 62.203 0.516 0.478 0.870 
We rapidly respond to 
competitive actions that 
threaten us 
42.31 62.770 0.519 0.401 0.869 
Top managers regularly discuss 
competitors’ strengths and 
strategies 
42.14 62.414 0.645 0.607 0.863 
We target customers where we 
have an opportunity for 
competitive advantage 
41.64 64.971 0.460 0.448 0.872 
We freely communicate 
information about our success 
and unsuccessful customer 
experiences across all business 
functions 
42.44 58.408 0.653 0.558 0.861 
All business functions (e.g. 
marketing/sales, manufacturing, 
R&D, finance/accounting, etc.) 
are integrated in serving the 
needs of our target markets 
41.95 62.155 0.566 0.460 0.867 
All business functions 
understand how everyone in 
our business can contribute to 
creating customer value 
41.94 60.272 0.689 0.587 0.860 
We share resources with other 
business units 42.25 61.609 0.456 0.467 0.875 
 
 
As outlined prior to undertaking the reliability analysis (3.5 Data Analyses), the criterion 
of a Cronbach’s alpha coefficient of 0.70 or higher for the MO instrument was achieved (α = 
0.876). 
 44 
4.4.1.2 MO factor analysis 
Factor analysis was conducted in order to test the dimensionality of the MO construct.  
The result of the factor analysis suggested that there were two factors.  The first factor was 
dominant as it accounted for 43.3 percent of the variance, while the second factor accounted for 
15.9 percent of the variance (Figure 4.1).  The principal component analysis (Table 4.11) showed 
all item-loading to the first component was above, or equal to, 0.544.  The loading on the second 
component was sporadic, showing no clear pattern.  
 
Figure 4.1  Market Orientation Scree Plot 
 45 
Table 4.11  Market Orientation Component Matrixa 
 
Component 
 
1 2 
All business functions understand how everyone 
in our business can contribute to creating 
customer value 
0.760  
We freely communicate information about our 
success and unsuccessful customer experiences 
across all business functions 
0.726  
We measure customer satisfaction 
systematically and frequently 0.719  
Our business objectives are driven primarily by 
customer satisfaction 0.716 -0.454 
Top managers regularly discuss competitors’ 
strengths and strategies 0.712 0.417 
Our strategy for competitive advantage is based 
on our understanding of customers’ needs 0.675 -0.589 
All business functions (e.g. marketing/sales, 
manufacturing, R&D, finance/accounting, etc.) 
are integrated in serving the needs of our target 
markets 
0.654  
We rapidly respond to competitive actions that 
threaten us 0.607  
Our business strategies are driven by our beliefs 
about how we can create greater value for 
customers 
0.594 -0.559 
All business functions share information 
concerning competitors’ strategies 0.593 0.482 
We target customers where we have an 
opportunity for competitive advantage 0.546  
We share resources with other business units 0.544 0.583 
Extraction Method: Principal Component Analysis 
a. 2 components extracted 
 
4.4.1.3 MO instrument conclusion 
  Based on Narver and Slater’s (1990) theoretical conceptualization of MO and results of 
the reliability and factor analysis, an unweighted average of MO’s 12 items was used as a 
composite index score to represent the construct in subsequent analyses. 
4.4.2 Alliance Orientation 
Kandermir, Yaprak, and Cavusgil (2006) “conceptualized alliance orientation as a 
competency that tends to increase in magnitude as each of the three fundamental alliance-driven 
capabilities, alliance scanning, alliance coordination, and alliance learning, increases” 
(Kandermir, Yaprak, and Cavusgil 2006, 331).  As Kandermir, Yaprak, and Cavusgil (2006) 
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viewed the AO construct as a composite of alliance scanning, alliance coordination, and alliance 
learning, they measured AO by using the unweighted mean score of the nine items. 
4.4.2.1 AO reliability 
In order to evaluate the internal reliability of the AO instrument, a reliability analysis was 
undertaken.  The nine-item AO instrument’s Cronbach’s alpha was 0.919, thereby exceeding the 
previously defined requirement (α ≥ 0.70).   Table 4.12 shows how Cronbach’s alpha would 
change if any of the nine items were deleted.     
Table 4.12  AO Total Statistics 
  
Scale mean if 
item deleted 
Scale 
variance if 
item deleted 
 
Corrected item-
total correlation 
Squared 
multiple 
correlation 
 
Cronbach’s alpha 
if item deleted 
We actively monitor our 
environment to identify 
partnering opportunities 
30.51 32.817 0.570 0.578 0.919 
We routinely gather 
information about prospective 
partners from various forums 
(e.g. trade shows, industry 
conventions, databases, 
publications, internet, etc.) 
30.54 32.302 0.595 0.697 0.918 
We are alert to market 
developments that create 
potential alliance opportunities 
30.63 33.030 0.595 0.556 0.918 
Our activities across different 
alliances are well coordinated 31.16 29.549 0.813 0.783 0.903 
We systematically coordinate 
our strategies across different 
alliances 
31.15 29.592 0.782 0.765 0.905 
We have processes to 
systematically transfer 
knowledge across alliance 
partners 
31.39 29.139 0.782 0.668 0.905 
We conduct periodic reviews of 
our alliances to understand 
what we are doing right and 
what we are doing wrong 
31.20 29.651 0.765 0.711 0.907 
We periodically collect and 
analyze field experiences from 
our alliances 
31.25 30.012 0.732 0.684 0.909 
We modify our alliance related 
procedures as we learn from 
experience 
31.04 29.934 0.778 0.740 0.906 
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  As outlined prior to undertaking the reliability analysis (3.5 Data Analyses), the 
criterion of a Cronbach’s alpha coefficient of 0.70 or higher for the AO instrument was achieved 
(α = 0.919). 
4.4.2.2 AO factor analysis 
Factor analysis was conducted in order to test the dimensionality of the AO construct.  
The result of the factor analysis suggested that there were two factors.  The first factor was 
dominant as it accounted for 60.9 percent of the variance, while the second factor accounted for 
14.6 percent of the variance (Figure 4.2).  The principal component analysis (Table 4.13) showed 
all item-loading to the first component was above, or equal to, 0.646.  The loading on the second 
component was sporadic, showing no clear pattern. 
 
Figure 4.2  Alliance Orientation Scree Plot 
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Table 4.13  Alliance Orientation Component Matrixa 
 
Component 
 
1 2 
Our activities across different alliances are well 
coordinated 0.864  
We systematically coordinate our strategies 
across different alliances 0.841  
We have processes to systematically transfer 
knowledge across alliance partners 0.839  
We modify our alliance related procedures as we 
learn from experience 0.834 -0.332 
We conduct periodic reviews of our alliances to 
understand what we are doing right and what we 
are doing wrong 
0.825 -0.353 
We periodically collect and analyze field 
experiences from our alliances 0.797 -0.331 
We routinely gather information about 
prospective partners from various forums (e.g. 
trade shows, industry conventions, databases, 
publications, internet, etc.) 
0.670 0.635 
We are alert to market developments that create 
potential alliance opportunities 0.668 0.500 
We actively monitor our environment to identify 
partnering opportunities 0.646 0.515 
Extraction Method: Principal Component Analysis 
a. 2 components extracted 
 
4.4.2.3 AO instrument conclusion 
  Based on Kandermir, Yaprak, and Cavusgil’s (2006) theoretical conceptualization of 
AO and the results of the reliability and factor analysis, an unweighted average of AO’s nine 
items was used as a composite index score to represent the construct in subsequent analyses.   
4.4.3 Business Performance 
4.4.3.1 PERF reliability  
In order to evaluate the internal reliability of the PERF instrument, a reliability analysis 
was undertaken.  The eight-item PERF instrument’s Cronbach’s alpha was 0.844, thereby 
exceeding the previously defined requirement (α ≥ 0.70).  Table 4.14 shows how Cronbach’s 
alpha would change if any of the eight items were deleted.     
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Table 4.14  Business Performance Total Statistics 
  
Scale mean if 
item deleted 
Scale 
variance if 
item deleted 
 
Corrected item-
total correlation 
Squared 
multiple 
correlation 
 
Cronbach’s alpha 
if item deleted 
Generation of new innovative 
products or projects 26.06 31.325 0.661 0.545 0.818 
New patents 
26.61 28.030 0.537 0.371 0.839 
Quality and relevance of 
scientific output 26.08 32.468 0.637 0.625 0.824 
Attainment of scientific results 
or milestones 26.17 30.905 0.714 0.730 0.813 
Recruitment of new personnel 
with outstanding knowledge 
and skills 
26.43 31.485 0.518 0.350 0.833 
Scientific or technological 
leadership in your environment 26.21 31.588 0.675 0.536 0.818 
Attainment of new capital, 
either public or private 26.96 29.248 0.493 0.338 0.843 
Maintenance and generation of 
alliances or partnerships 26.66 29.384 0.624 0.441 0.819 
 
4.4.3.2 PERF factor analysis  
Factor analysis was conducted in order to test the dimensionality of the PERF construct.  
The results showed that only one factor had a eigenvalue greater than one, indicating 
unidimensionality (Figure 4.3).  Table 4.15 shows how each individual item loaded on a single 
factor. 
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Figure 4.3  Business Performance Scree Plot 
Table 4.15  Business Performance Component Matrixa 
 
Component 
 
1 
Generation of new innovative products or 
projects 0.775 
New patents 0.646 
Quality and relevance of scientific output 0.763 
Attainment of scientific results or milestones 0.841 
Recruitment of new personnel with 
outstanding knowledge and skills 0.651 
Scientific or technological leadership in your 
environment 0.774 
Attainment of new capital, either public or 
private 0.578 
Maintenance and generation of alliances or 
partnerships 0.709 
Extraction Method: Principal Component Analysis 
a. 1 components extracted 
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4.4.3.3 PERF instrument conclusion 
  Based on results of the reliability and factor analysis, an unweighted average of PERF’s 
eight items was used as a composite index score to represent the construct in subsequent 
analyses.   
4.5 Non-response Bias 
Questionnaires that were received up to and including the week of the second mailing 
(June 25, 2012) were deemed early responses, while all others received after that week were 
regarded as late responses.  Of the 81 usable responses, 58 were classified as early and 23 were 
classified as late responses.   
Leveraging the works of Armstrong and Overton (1977), independent sample t-tests were 
conducted to compare the group of companies classified as early responders and the group of 
companies classified as late responders, based on their group mean scores of MO, AO, and 
PERF.  There were no differences among the groups’ MO (t(79) = 0.233, p = 0.816), AO (t(78) = 
-0.840, p = 0.404), or PERF (t(77) = -0.611, p = 0.543) scores.  
4.6 Discriminant Validity 
Discriminant validity between MO and AO was tested using group mean scores.  Table 
4.16 shows the correlations between MO and AO’s group mean scores. 
Table 4.16  Correlationsb 
  MO AO 
MO Pearson Correlation 
Sig. (2-tailed) 
1 
 
 
AO Pearson Correlation 
Sig. (2-tailed) 
0.469 
0.000 
1 
b. Listwise  N=80 
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The correlation coefficient between MO and AO was 0.469, the standard error was 0.098, 
and the 90 percent confidence interval was 0.296 ≤ r ≤ 0.622.  This confidence interval did not 
contain the number one, suggesting that acceptable discriminant validity between the group 
means was achieved (Kline 2005).  
4.7 Descriptive Analyses 
The subsequent sections use the descriptive items (response language, method of 
completion, science park location, association memberships, ownership structure, CEO’s 
education, company age, and company size) as independent variables and the three main 
constructs (MO, AO, and PERF) as dependent variables in additional analyses. 
4.7.1 Response Language 
Independent sample t-tests were conducted to compare the group of companies that 
completed the questionnaires in English and the group of companies that completed 
questionnaires in French, based on their group mean scores of MO, AO, and PERF.  There was a 
statistically significant difference (t(77) = -2.788, p = 0.010) between the English-speaking 
group’s (3.684 ± 0.790) and the French-speaking group’s (4.173 ± 0.527) PERF scores.  
However, there were no statistically significant differences among the groups’ MO (t(79) = -
0.353, p = 0.725) and AO (t(78) = -1.420, p = 0.160) scores. 
4.7.2 Method of Completion 
Independent sample t-tests were conducted to compare the group of companies that 
responded by mail and the group of companies that responded online, based on their group mean 
scores of MO, AO, and PERF.  There were no statistically significant differences among the 
groups’ MO (t(79) = 0.484, p = 0.630), AO (t(78) = 0.090, p = 0.929), and PERF (t(77) = 0.349, 
p = 0.728) scores. 
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4.7.3 Science Park Location 
Independent sample t-tests were conducted to compare the group of companies located in 
science parks and the group of companies located outside of science parks, based on their group 
mean scores of MO, AO, and PERF.  There were no statistically significant differences among 
the groups’ MO (t(78) = -0.779, p = 0.439), AO (t(78) = -1.083, p = 0.282), and PERF (t(77) = 
0.001, p = 0.999) scores. 
4.7.4 Association Memberships 
Three linear regression analyses were performed using the number of association 
memberships as the independent variable and MO, AO, and PERF alternating as the dependent 
variable.  The results of the regression models indicated that the number of association 
memberships had no statistically significant effects on MO (R2 = 0.023, F(1, 79) = 1.896, p = 
0.172), AO (R2 = 0.036, F(1, 78) = 2.901, p = 0.093), and PERF (R2 = 0.017, F(1, 77) = 1.314, p 
= 0.255).   
4.7.5 Ownership Structure 
Originally, ownership structures were categorized into four groups (Table 4.3).  
However, due to the small number of responses in two categories (subsidiary and non-profit), 
they were omitted, leaving two ownership groups.  The remaining ownership groups were 
privately owned and publicly traded.   
Independent sample t-tests were conducted to compare the group of companies that were 
privately owned and the group of companies that were publicly traded, based on their group 
mean scores of MO, AO, and PERF.  There was a statistically significant difference (t(72) = 
2.687, p = 0.009) between the privately owned group’s (3.928 ± 0.674) and the publicly traded 
group’s (3.353 ± 0.824) MO scores.  However, there were no statistically significant differences 
among the groups’ AO (t(72) = -0.098, p = 0.922) and PERF (t(71) = 0.224, p = 0.823) scores. 
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4.7.6 Educational Background 
Originally, educational backgrounds of CEOs were categorized into eight groups (Table 
4.4).  Due to the small number of responses in several categories (e.g. engineering and arts), 
educational background categories were collapsed into five groups, namely doctoral, business, 
medical/science, hybrid, and other.   
ANOVAs were conducted to compare groups of companies with CEOs that had varying 
educational background, based on their group mean scores of MO, AO, and PERF.  There were 
no statistically significant differences among the groups’ MO (F(4, 76) = 0.303, p = 0.516), AO 
(F(4,75) = 0.505, p = 0.732), and PERF (F(4,74) = 0.212, p = 0.931) scores. 
4.7.7 Company Age 
Three linear regression analyses were performed using the age of companies as the 
independent variable and MO, AO, and PERF alternating as the dependent variable.  The results 
of the first two regression models indicated that the age of companies had no statistically 
significant effects on MO (R2 = 0.001, F(1, 78) = 0.099, p = 0.754) and AO (R2 = 0.069, F(1, 78) 
= 0.378, p = 0.541).  However, the third regression model indicated that the age of companies 
had a negative and statistically significant effect on PERF (R2 = 0.321, F(1, 77) = 8.842, p = 
0.004). 
4.7.8 Company Size  
Originally, companies were classified as micro, small, medium, and large (Table 4.6).  
Due to the small number of responses in the medium and large categories, only companies in the 
micro and small categories were compared. 
Independent sample t-tests were conducted to compare the group of companies that were 
categorized as micro and the group of companies that were categorized as small, based on their 
group mean scores of MO, AO, and PERF.  There were no statistically significant differences 
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among the groups’ MO (t(70) = -0.992, p = 0.325), AO (t(70) = -0.867, p = 0.389), and PERF 
(t(69) = 0.211, p = 0.834) scores. 
4.7.9 Descriptive Analyses Conclusion 
The preceding analyses yielded few statistically significant results.  Therefore, 
descriptive characteristics were not included in the subsequent regression analyses. 
4.8 Regression Analyses 
For each respondent, the 12 MO items were unweighted and averaged, the nine AO items 
were unweighted and averaged, and the eight PERF items were unweighted and averaged, 
creating MO, AO, and PERF composite index scores.  In the subsequent sections, these 
composite index scores were used in regression analyses.   
4.8.1 Market Orientation and Business Performance 
Linear regression was performed using MO as the independent variable and PERF as the 
dependent variable.   
PERF = β(MO) + C 
In order to treat missing data, listwise deletion was employed.  Tables 4.17, 4.18, and 
4.19 show the results from the regression analysis. 
Table 4.17  H1 Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.303a 0.092 0.080 0.74063 
  a. Predictors: (Constant), MO 
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Table 4.18  H1 ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
4.273 
42.237 
46.510 
1 
77 
78 
4.273 
0.549 
7.790 0.007b 
a. Dependent Variable: PERF 
b. Predictors: (Constant), MO 
 
Table 4.19  H1 Coefficientsa 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
MO 
2.514 
0.329 
0.455 
0.118 
 
0.303 
5.521 
2.791 
0.000 
0.007 
a. Dependent Variable: PERF 
 
The result of this regression model indicated that MO had a positive and statistically 
significant effect (β = 0.329, p = 0.007) on PERF (R2 = 0.092, F(1, 77) = 7.790, p = 0.007).  The 
regression model was as follows: 
PERF = 0.329(MO) + 2.514 
According to G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 
0.101, an error probability of α = 0.05, one predictor variable (MO), and a total sample size of 
79, achieved power (1-β) was 0.80, meeting the minimum power requirement (1-β = 0.80) as 
suggested by Cohen (1988). 
4.8.2 Alliance Orientation and Performance 
Linear regression was performed using AO as the independent variable and PERF as the 
dependent variable.   
PERF = β(AO) + C 
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In order to treat missing data, listwise deletion was employed.  Tables 4.20, 4.21, and 
4.22 show the results from the regression analysis. 
Table 4.20  H2 Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.668a 0.446 0.439 0.57835 
  a. Predictors: (Constant), AO 
 
Table 4.21  H2 ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
20.754 
25.756 
46.510 
1 
77 
78 
20.754 
0.334 
62.046 0.000b 
a. Dependent Variable: PERF 
b. Predictors: (Constant), AO 
 
Table 4.22  H2 Coefficientsa 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
AO 
0.902 
0.737 
0.369 
0.094 
 
0.668 
2.442 
7.877 
0.017 
0.000 
a. Dependent Variable: PERF 
 
The result of this regression model indicated that AO had a positive and statistically 
significant effect (β = 0.737, p < 0.001) on PERF (R2 = 0.446, F(1, 77) = 62.046, p < 0.001).  
The regression model was as follows: 
PERF = 0.737(AO) + 0.902 
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According to G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 
0.805, an error probability of α = 0.05, one predictor variable (AO), and a total sample size of 79, 
achieved power (1-β) was 1.00, exceeding the minimum power requirement (1-β = 0.80) as 
suggested by Cohen (1988).  
4.8.3 Market Orientation, Alliance Orientation, and Business Performance 
Linear regression was performed using MO and AO as the independent variables and 
PERF as the dependent variable.   
PERF = β1(MO) + β2(AO) + C 
In order to treat missing data, listwise deletion was employed.  Tables 4.23, 4.24, and 
4.25 show the results from the regression analysis.     
Table 4.23  H3 Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.668a 0.446 0.432 0.58207 
  a. Predictors: (Constant), AO, MO 
 
Table 4.24  H3 ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
20.761 
25.749 
46.510 
2 
76 
78 
10.380 
0.339 
30.638 0.000b 
a. Dependent Variable: PERF 
b. Predictors: (Constant), AO, MO 
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Table 4.25  H3 Coefficients a 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
MO 
AO 
0.930 
-0.015 
0.744 
0.424 
0.105 
0.107 
 
-0.014 
0.674 
2.195 
-0.141 
6.976 
0.031 
0.888 
0.000 
a. Dependent Variable: PERF 
 
The result of this regression model indicated that AO had a positive and statistically 
significant effect (β2 = 0.744, p < 0.001) on PERF and MO had a non-significant effect (β1 = -
0.015, p = 0.888) on PERF (R2 = 0.446, F(2, 76) = 30.638, p < 0.001).  The regression model 
was as follows: 
PERF = -0.015(MO) + 0.744(AO) + 0.930 
According to G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 
0.805, an error probability of α = 0.05, two predictor variables (MO and AO), and a total sample 
size of 79 achieved power (1-β) was 1.00, exceeding the minimum power requirement (1-β = 
0.80) as suggested by Cohen (1988). 
4.8.4 Market Orientation and Alliance Orientation 
Linear regression was performed using MO as the independent variable and AO as the 
dependent variable.   
AO = β(MO) + C 
In order to treat missing data, listwise deletion was employed.  Tables 4.26, 4.27, and 
4.28 show the results from the regression analysis.     
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Table 4.26  Mediation Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.469a 0.220 0.210 0.61856 
  a. Predictors: (Constant), MO 
 
Table 4.27  Mediation ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
8.415 
29.844 
38.259 
1 
78 
79 
8.415 
0.383 
21.992 0.000b 
a. Dependent Variable: AO 
b. Predictors: (Constant), MO 
 
Table 4.28  Mediation Coefficients a 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
MO 
2.139 
0.459 
0.379 
0.098 
 
0.469 
5.642 
4.690 
0.000 
0.000 
a. Dependent Variable: AO 
 
The result of this regression model indicated that MO had a positive and statistically 
significant effect (β = 0.459, p < 0.001) on AO (R2 = 0.220, F(1, 78) = 21.992, p < 0.001).  The 
regression model was as follows: 
AO = 0.459(MO) + 2.139 
According to G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 
0.282, an error probability of α = 0.05, one predictor variable (MO), and a total sample size of 80 
achieved power (1-β) was 1.00, exceeding the minimum power requirement (1-β = 0.80) as 
suggested by Cohen (1988). 
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4.9 Post-Hoc Analyses 
4.9.1 Market Orientation and Business Performance 
An additional linear regression was performed to examine MO’s effect on PERF, with 
control variables added.  These control variables included whether a company was located in a 
science park (SP), the number of association memberships held by a company (AM), the 
ownership structure, age of companies (AGE), and the number of employees (SIZE).  Because 
the company ownership structure is a categorical variable with five options (e.g. privately 
owned, publicly traded, subsidiary, non-profit, and other), three dummy variables (n-1) were 
created and included in the regression model.  These three dummy variables consider whether a 
company was privately owned (PO), publicly traded (PT), or a subsidiary (SUB).  In order to 
treat missing data, listwise deletion was employed.  Tables 4.29, 4.30, and 4.31 show the results 
from the regression analysis.     
Table 4.29  Post-Hoc H1 Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.515a 0.265 0.180 0.68903 
  a. Predictors: (Constant), MO, SP, AM, PO, PT, SUB, AGE, SIZE 
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Table 4.30  Post-Hoc H1 ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
11.797 
32.759 
44.555 
8 
69 
77 
1.475 
0.475 
3.106 0.005b 
a. Dependent Variable: PERF 
b. Predictors: (Constant), MO, SP, AM, PO, PT, SUB, AGE, SIZE 
 
Table 4.31  Post-Hoc H1 Coefficients a 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
MO 
SP 
AM 
PO 
PT 
SUB 
AGE 
SIZE 
2.608 
0.349 
-0.043 
0.034 
0.135 
0.242 
-0.360 
0.023 
0.000 
0.664 
0.119 
0.178 
0.062 
0.500 
0.526 
0.609 
0.008 
0.000 
 
0.328 
-0.027 
0.062 
0.077 
0.119 
-0.105 
-0.313 
-0.126 
3.927 
2.926 
-0.240 
0.545 
0.270 
0.549 
-0.592 
-2.944 
-1.178 
0.000 
0.005 
0.811 
0.587 
0.788 
0.647 
0.556 
0.004 
0.243 
a. Dependent Variable: PERF 
 
Controlling for SP, AM, PO, PT, SUB, AGE, and SIZE, MO had a positive and 
statistically significant effect (β1 = 0.349, p = 0.005) on PERF (R2 = 0.265, F(8, 69) = 3.106, p = 
0.005).  According to G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 
0.361, an error probability of α = 0.05, eight predictor variables (MO, SP, AM, PO, PT, SUB, 
AGE, SIZE), and a total sample size of 77, achieved power (1-β) was 1.00, exceeding the 
minimum power requirement (1-β = 0.80) as suggested by Cohen (1988). 
4.9.2 Alliance Orientation and Business Performance 
An additional linear regression was performed to examine AO’s effect on PERF, with the 
aforementioned control variables added.  In order to treat missing data, listwise deletion was 
employed.  Tables 4.32, 4.33, and 4.34 show the results from the regression analysis.     
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Table 4.32  Post-Hoc H2 Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.762a 0.581 0.532 0.52014 
  a. Predictors: (Constant), AO, SP, AM, PO, PT, SUB, AGE, SIZE 
 
Table 4.33  Post-Hoc H2 ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
25.888 
18.667 
44.555 
8 
69 
77 
3.236 
0.271 
11.961 0.000b 
a. Dependent Variable: PERF 
b. Predictors: (Constant), AO, SP, AM, PO, PT, SUB, AGE, SIZE 
 
Table 4.34  Post-Hoc H2 Coefficients a 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
AO 
SP 
AM 
PO 
PT 
SUB 
AGE 
SIZE 
0.734 
0.752 
0.109 
0.006 
0.383 
0.265 
0.473 
-0.020 
0.000 
0.544 
0.092 
0.136 
0.046 
0.377 
0.396 
0.471 
0.006 
0.000 
 
0.696 
0.068 
0.011 
0.218 
0.131 
0.138 
-0.269 
-0.121 
1.349 
8.192 
0.800 
0.131 
1.016 
0.668 
1.005 
-3.358 
-1.510 
0.182 
0.000 
0.426 
0.896 
0.313 
0.506 
0.318 
0.001 
0.136 
a. Dependent Variable: PERF 
 
Controlling for SP, AM, PO, PT, SUB, AGE, and SIZE, AO had a positive and 
statistically significant effect (β1 = 0.752, p < 0.001) on PERF (R2 = 0.581, F(8, 69) = 11.961, p 
< 0.001).  According to G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 
1.387, an error probability of α = 0.05, eight predictor variables (MO, SP, AM, PO, PT, SUB, 
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AGE, SIZE), and a total sample size of 77, achieved power (1-β) was 1.00, exceeding the 
minimum power requirement (1-β = 0.80) as suggested by Cohen (1988). 
4.9.3 Market Orientation, Alliance Orientation, and Business Performance 
An additional linear regression was performed to examine MO and AO’s effects on 
PERF, with the aforementioned control variables added.  In order to treat missing data, listwise 
deletion was employed.  Tables 4.35, 4.36, and 4.37 show the results from the regression 
analysis.     
Table 4.35  Post-Hoc H3 Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.762a 0.581 0.526 0.52395 
  a. Predictors: (Constant), MO, AO, SP, AM, PO, PT, SUB, AGE, SIZE 
 
Table 4.36  Post-Hoc H3 ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
25.889 
18.667 
44.555 
9 
68 
77 
2.876 
0.275 
10.478 0.000b 
a. Dependent Variable: PERF 
b. Predictors: (Constant), MO, AO, SP, AM, PO, PT, SUB, AGE, SIZE 
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Table 4.37  Post-Hoc H3 Coefficients a 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
MO 
AO 
SP 
AM 
PO 
PT 
SUB 
AGE 
SIZE 
0.732 
0.001 
0.751 
0.109 
0.006 
0.383 
0.265 
0.473 
-0.020 
0.000 
0.569 
0.103 
0.105 
0.137 
0.047 
0.382 
0.400 
0.477 
0.006 
0.000 
 
0.001 
0.695 
0.068 
0.011 
0.218 
0.131 
0.138 
-0.269 
-0.121 
1.286 
0.013 
7.164 
0.794 
0.126 
1.003 
0.663 
0.991 
-3.320 
-1.498 
0.203 
0.990 
0.000 
0.430 
0.900 
0.319 
0.510 
0.325 
0.001 
0.139 
a. Dependent Variable: PERF 
 
Controlling for SP, AM, PO, PT, SUB, AGE, and SIZE, AO had a positive and 
statistically significant effect (β2 = 0.751, p < 0.001) on PERF and MO had a non-significant 
effect (β1 = 0.001, p = 0.990) on PERF (R2 = 0.581, F(9, 68) = 10.478, p < 0.001).  According to 
G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 1.387, an error probability 
of α = 0.05, nine predictor variables (MO, AO, SP, AM, PO, PT, SUB, AGE, SIZE), and a total 
sample size of 77, achieved power (1-β) was 1.00, exceeding the minimum power requirement 
(1-β = 0.80) as suggested by Cohen (1988). 
4.9.4 Market Orientation and Alliance Orientation  
An additional linear regression was performed to examine MO’s effect on PERF, with the 
aforementioned control variables added.  In order to treat missing data, listwise deletion was 
employed.  Tables 4.38, 4.39, and 4.40 show the results from the regression analysis.     
Table 4.38  Post-Hoc Mediation Model Summary 
Model R R2 Adj. R2 Std. Error of the 
Estimate 
1 0.588a 0.346 0.271 0.59755 
  a. Predictors: (Constant), MO, SP, AM, PO, PT, SUB, AGE, SIZE 
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Table 4.39  Post-Hoc Mediation ANOVAa 
 Sum of Squares df Mean Square F Sig. 
Regression 
Residual 
Total 
13.214 
24.995 
38.208 
8 
70 
78 
1.652 
0.357 
4.626 0.000b 
a. Dependent Variable: AO 
b. Predictors: (Constant), MO, SP, AM, PO, PT, SUB, AGE, SIZE 
 
Table 4.40  Post-Hoc Mediation Coefficients a 
 Unstandardized Coefficients Standardized Coefficients   
 B Std. Error Beta t Sig. 
(Constant) 
MO 
SP 
AM 
PO 
PT 
SUB 
AGE 
SIZE 
2.505 
0.461 
-0.205 
0.037 
-0.332 
-0.032 
-1.111 
-0.004 
0.000 
0.574 
0.103 
0.152 
0.054 
0.433 
0.456 
0.528 
0.007 
0.000 
 
0.471 
-0.140 
0.074 
-0.204 
-0.017 
-0.350 
-0.062 
-0.005 
4.363 
4.489 
-1.351 
0.695 
-0.767 
-0.070 
-2.105 
-0.624 
-0.053 
0.000 
0.000 
0.181 
0.489 
0.446 
0.944 
0.039 
0.535 
0.958 
a. Dependent Variable: AO 
 
Controlling for SP, AM, PO, PT, SUB, AGE, and SIZE, MO had a positive and 
statistically significant effect (β1 = 0.461, p < 0.001) on AO (R2 = 0.346, F(8, 70) = 4.626, p < 
0.001).  According to G*Power’s (1996) post hoc power analysis, with an effect size of ƒ2 = 
0.529, an error probability of α = 0.05, eight predictor variables (MO, SP, AM, PO, PT, SUB, 
AGE, SIZE), and a total sample size of 78 achieved power (1-β) was 1.00, exceeding the 
minimum power requirement (1-β = 0.80) as suggested by Cohen (1988). 
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CHAPTER 5 
DISCUSSION 
5.1 Responses 
The number of responses received was greater than, or similar to, other studies examining 
MO in the biotechnology industry (Appiah-Adu and Ranchhod 1998; De Luca, Verona, and 
Vicari 2010; Renko, Carsrud, and Brannback 2009).  Appiah-Adu and Ranchhod (1998) received 
62 usable responses in their study of UK biotechnology companies, De Luca, Verona, and Vicari 
(2010) received 70 usable responses from Italian biotechnology companies, and Renko, Carsrud, 
and Brannback (2009) received 85 responses when researching the biotechnology industry in the 
US and Scandinavia.  Comparatively, the number of responses received was favourable to 
similar studies of MO in the biotechnology industry. 
5.2 Demographics 
Dillman (1978) suggests that obtaining a local endorsement can increase the number of 
responses in a study (Dillman 1978).  The collaboration with UQAM allowed for questionnaires 
to be translated from English into French.  Additionally, the endorsement from the university 
may have helped legitimize the study among the French-speaking business community.  Dillman 
(2000) suggests that the number of responses can be increased by employing a multi-modal 
approach (e.g. mail and online) (Dillman 2000).  This study’s online completion option aided in 
generating 20 additional responses, supporting Dillman’s (2000) recommendations. 
Table 4.1 shows the number and percentage of companies located in each province and 
the number and percentage of responses from each province.  The percentages of responses from 
British Columbia, Alberta, Saskatchewan, Prince Edward Island, and Nova Scotia were greater 
than the percentages of companies located in the provinces.  The percentages of responses from 
Manitoba, Ontario, Quebec, and Newfoundland and Labrador were less than the percentages of 
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companies located in the provinces.  However, only Alberta, Ontario, and Quebec’s differences 
exceeded five percent.  Overall, the percentage of responses from each province closely 
resembled the percentage of companies located in each province. 
   The number of biotechnology industry associations is increasing as they are playing an 
important role in advancing innovation (Bagchi-Sen, Smith, and Hall 2004).  Furthermore, 
biotechnology industry associations are said to be central to the biopartnering process, as they 
encourage companies to form partnerships and collaborate to mutually benefit (Baum, Calabrese, 
and Silverman 2000).  In the US, most states have at least one biotechnology association 
(Bagchi-Sen, Smith, and Hall 2004).  Similarly, in Canada, there are national, regional, and 
provincial biotechnology associations (BIOTECanada 2011c; Life Sciences Association of 
Manitoba 2012).  Seventy-nine percent of the respondents from this study held at least one 
biotechnology association membership, reiterating their perceived importance. 
   Most biotechnology companies in Canada are SMEs (Conference Board of Canada 
2005; Datamonitor 2011b; Rajamaki 2008; Government of Canada 2012; BIOTECanada 2011b).  
Using Industry Canada’s (2011) employment size categories, the majority of responses from this 
study were from micro (16%) or small (71.6%) companies.  Therefore, the number of responses 
from SMEs were consistent with industry statistics and reflective of the population. 
 5.3 Reliability 
All of the instruments’ Cronbach’s alpha coefficients exceeded the previously defined 
requirement (α ≥ 0.70).  The MO instrument’s Cronbach’s alpha coefficient was 0.876, a good 
internal reliability coefficient as described by George and Mallery (2009).  It was expected that a 
lower Cronbach’s alpha coefficient would be obtained because Narver and Slater’s (1990) MO 
instrument had not been used in the Canadian medical/healthcare subsector of the biotechnology 
industry.  However, the internal reliability coefficient obtained from the MO instrument 
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exceeded expectations.  The favourable Cronbach’s alpha coefficient signified that all of the 
items were correlated with each other and measured the same phenomenon (e.g. MO) (SAGE 
Research Methods 2012b).  This could be the result of the instrument’s extensive use and the 
advanced practices of MO research. 
The Kandemir, Yaprak, and Cavusgil (2006) AO instrument was developed to measure 
the acquisition, interpretation, and use of alliance management knowledge in the US technology 
industry, where the presence of strategic alliances among technology companies are increasing 
and of growing importance (Hagedoorn and Duysters 2002; Gulati 1998; Verspagen and 
Duysters 2004).  The AO instrument’s Cronbach’s alpha coefficient was 0.919, an excellent 
internal reliability coefficient as described by George and Mallery (2009).  It was expected that a 
lower Cronbach’s alpha coefficient would be obtained because of the limited research utilizing 
the AO instrument.  However, the internal reliability coefficient obtained from the AO 
instrument exceeded expectations, signifying that all of the items were correlated with each other 
and measured the same phenomenon (e.g. AO).  This may have been due to the similarities 
between this empirical setting (e.g. biotechnology industry) and the empirical setting for which 
the instrument was developed (e.g. technology industry).  Specifically, the technology industry is 
similar to the biotechnology industry as organizational success has been shown to rely on 
effective strategic alliance management (Baum, Calabrese, and Silverman 2000; Baum and 
Silverman 2004; Forest and Martin 1992; George et al. 2001; Sarkar, Echambadi, and Harrison 
2001).  
The PERF instrument’s Cronbach’s alpha coefficient was 0.844, a good reliability 
coefficient as described by George and Mallery (2009).  It was expected that a lower Cronbach’s 
alpha coefficient would be obtained because the PERF instrument, created by adapting and 
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broadening the De Luca, Verona, and Vicari (2010) R&D effectiveness instrument, had never 
been empirically tested prior to this study.  Obtaining a Cronbach’s alpha coefficient of 0.70 is 
generally accepted and justified when instruments are new and used in exploratory work 
(Nunnally 1978).  The internal reliability coefficient obtained from the PERF instrument 
exceeded expectations, signifying that all of the items were correlated with each other and 
measured the same phenomenon (e.g. PERF).  Adapting and broadening the R&D effectiveness 
instrument to include items related to capital, alliances and partnerships, and milestones may 
have been the reason for its success in this study.  
5.4 Non-response Bias 
Analyses were performed (4.5 Non-response Bias) in order to determine the presence, or 
absence, of a non-response bias.  No statistically significant differences were found in the 
analyses, suggesting that early and late responders did not differ.  Statistically, as early and late 
responders did not significantly differ, there was no evidence that supported the existence of a 
non-response bias (Armstrong and Overton 1977). 
5.5 Descriptive Analyses 
5.5.1 Response Language 
The results from the independent sample t-tests, that compared the group of companies 
that completed the questionnaires in English and the group of companies that completed the 
questionnaires in French, showed no statistically significant differences among the groups’ MO 
or AO scores (4.7.1 Response Language).  There was a statistically significant difference 
between the English-speaking group’s and the French-speaking group’s PERF scores.  
Statistically, the mean PERF score of French-speaking companies was significantly higher than 
the English-speaking companies MO score, suggesting that French-speaking companies 
outperformed English-speaking companies.   
 71 
Practically, there are two possible explanations for the statistically significant finding.  
The first explanation for the statistically significant finding is that French-speaking companies 
slightly outperformed English-speaking companies.  A second explanation for the statistically 
significant finding is that French-speaking companies have a slightly higher perceived valuation 
of performance than English-speaking companies.   
5.5.2 Method of Completion 
Kwak and Radler (2002) found that respondents differed based on data collection 
formats.  The results from the independent sample t-tests, that compared the group of companies 
that responded by mail and the group of companies that responded online, showed no statistically 
significant differences among the groups’ MO, AO, or PERF scores (4.7.2 Method of 
Completion).  This refutes Kwak and Radler’s (2002) findings, suggesting that respondents did 
not differ based on data collection formats.  An explanation for this may be that all respondents 
in the biotechnology industry are technologically-oriented, and the method of completion is not a 
measure of their organization’s performance record nor its orientation to the market and 
alliances.  
5.5.3 Science Park Location 
It has been shown that positive externalities and other economic benefits can occur when 
similar companies geographically cluster around, and knowledge share with, one another (Folta, 
Cooper, and Baik 2006; Efendioglu 2005).  However, Folta, Cooper, and Baik (2009) found that 
large biotechnology clusters can actually inhibit positive economic benefits and even cause 
negative externalities for companies.   
The results from the independent sample t-tests, that compared the group of companies 
located in science parks and the group of companies located outside of science parks, showed no 
differences among the groups’ MO, AO, or PERF scores (4.7.3 Science Park Location).  This 
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suggests that geographical clustering does not increase or decrease Canadian medical/healthcare 
biotechnology companies’ MO, AO, or PERF.   
One explanation for the non-significant differences is that companies with close 
geographical proximity may not actually be participating in knowledge-sharing.  Moreover, it is 
possible that the importance of geographical clustering could be overstated, resulting in the 
interpretation that clustering positively influences performance.  Secondly, companies that are 
geographically clustered may have dissimilar focuses, resulting in little or no knowledge-sharing.  
Another explanation is that, due to the peculiarities of the Canadian medical/healthcare subsector 
of the biotechnology industry, clustering is not as important as being market-oriented or alliance-
oriented.   
5.5.4 Association Memberships 
Association memberships have been shown to advance innovation in the biotechnology 
industry (Bagchi-Sen, Smith, and Hall 2004).  Yet, according to Baum, Calabrese, and Silverman 
(2000), Canadian biotechnology companies that had numerous industry association memberships 
performed poorly.  Baum, Calabrese, and Silverman (2000) suggested that companies that hold 
several association memberships do so to make up for founders’ lack, or size, of professional 
networks. 
The number of association memberships were used as the independent variable and MO, 
AO, and PERF were used as the dependent variable in regression analyses.  Results indicated 
that the number of association memberships did not affect MO, AO, or PERF (4.7.4 Association 
Memberships).  The number of industry association memberships that medical/healthcare 
biotechnology companies have does not appear to influence its MO, AO, or PREF scores.  This 
refutes Baum, Calabrese, and Silverman’s (2000) findings that suggest association memberships 
dampen performance.  One reason for this incongruence could be that industry association 
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memberships matter more in the medical/healthcare subsector as opposed to the entire Canadian 
biotechnology industry, as they did not lower performance.  Secondly, it could be related to the 
timing of the two studies, as they were conducted over 10 years apart.  Finally, it could be related 
to the process of obtaining an association membership, as most associations only require its 
members to pay an annual fee (Newfoundland and Labrador Association of Technology 
Industries 2013; Life Sciences British Columbia 2012; BioNova 2013; BioAlberta 2013; 
BIOTECanada 2013; Ag-West Bio 2013).  Furthermore, many biotechnology associations allow 
non-biotechnology companies (e.g. accounting firms) to hold memberships (Newfoundland and 
Labrador Association of Technology Industries 2013; Life Sciences British Columbia 2012; 
BioNova 2013; BioAlberta 2013; BIOTECanada 2013; Ag-West Bio 2013).  Overall, no 
evidence was found to suggest that industry association memberships increased or decreased 
MO, AO, or PERF. 
5.5.5 Ownership Structure 
The differences in biotechnology ownership types have been shown to influence 
companies’ corporate strategies and performance (Baum, Calabrese, and Silverman 2000; Stuart, 
Hoang, and Hybels 1999; Zahra 1996).  Zahra (1996) showed that independent biotechnology 
companies outperformed corporate-sponsored biotechnology companies.  Stuart (1999) 
demonstrated how biotechnology companies with established partners issued stock and had 
higher initial valuations than companies without such partners.     
The results from the independent sample t-tests that compared the group of companies 
that were privately owned and the group of companies that were publicly traded, showed no 
statistically significant differences among the groups’ AO or PERF scores (4.7.5 Ownership 
Structure).  This contrasts previous findings that suggest differing ownership types influence 
performance.  Leveraging the results from this study’s hypotheses to rationalize the ownership 
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structure findings, it can be said that a business’ performance is influenced more by its 
behavioural commitments, organizational culture, and activities than its legal structure.       
There was a statistically significant difference between the privately owned group’s and 
the publicly traded group’s MO scores.  Statistically, the mean MO score of privately owned 
companies was significantly higher than the publicly traded mean MO score, suggesting that 
privately owned companies were more market-oriented.  When a company becomes publicly 
traded it is accountable to new people, namely the shareholders.  Perhaps this new accountability 
shifts some of the organizational focus from customers, competitors, and business units to 
shareholders, resulting in a decrease in MO.  Although a statistically significant difference was 
found between the two MO scores, the MO score of publicly traded companies was not low.  
Therefore, privately owned and publicly traded Canadian medical/healthcare biotechnology 
companies are market-oriented, but by how much may be dependent on companies’ stakeholders.   
5.5.6 Educational Background 
The importance of the educational background of biotechnology CEOs has been widely 
debated (Kermani and Gittins 2004; McMillan and Thomas 2005; Patzelt 2010).  The education 
of biotechnology CEOs has been shown to influence a company’s meaningfulness of patents, 
valuation at the time of initial public offering, and stock price (McMillan and Thomas 2005).  
Conversely, Patzelt (2010) found that in a cross-cultural study of European and US 
biotechnology companies, education of CEOs did not influence financial performance (Patzelt 
2010).  
ANOVAs were conducted to compare groups of companies with CEOs that had varying 
educational backgrounds, based on their group mean MO, AO, and PERF scores.  No statistically 
significant differences were found among the groups’ MO, AO, or PERF scores (4.7.6 
Educational Background).  The educational backgrounds of CEOs seemed to play no role in 
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determining companies’ performance or orientation to the market and alliances.  It is possible 
that Canadian medical/healthcare biotechnology CEOs who have specific skills, surround 
themselves with other individuals who have complementary knowledge and experience.  It may 
be that this effective management of knowledge and experience enables all types of managers to 
perform optimally.   
5.5.7 Company Age 
A study of US biotechnology companies showed that the stock market favoured older and 
more established companies (McMillan and Thomas 2005).  Conventional wisdom suggests that 
companies that successfully move through the organizational lifecycle, reach profitability and 
perform well, or at least well enough for continued existence.   
The age of companies was used as the independent variable and MO, AO, and PERF 
were used as the dependent variable in regression analyses.  Results indicated that the age of 
companies did not have statistically significant effects on MO or AO (4.7.7 Company Age).  
However, the age of companies had a statistically significant effect on PERF (4.7.7 Company 
Age).  Specifically, the age of companies had a negative influence on PERF.  Therefore, younger 
companies performed more favourably than older companies, refuting McMillan’s (2005) 
findings.  These results suggest younger companies perform well financially, securing private 
and public capital.  Furthermore, younger companies are better able to secure patents, attain 
milestones, recruit new personnel, and demonstrate technological leadership as opposed to their 
older counterparts.  This should be interpreted with caution, as this does not necessarily mean 
that older companies perform poorly, but perhaps there are more deliverables in the early years. 
5.5.8 Company Size 
In Woiceshyn and Hartel’s (1996) study of Canadian biotechnology companies they 
found that sales performance increased with company size.  The results from the independent 
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sample t-tests that compared the group of companies that were categorized as micro and the 
group of companies that were categorized as small, showed no statistically significant 
differences among the groups’ MO, AO, or PERF scores (4.7.8 Company Size).  This suggests 
that micro and small companies do not differ in terms of overall performance or their orientation 
to marketing and alliance management.  It is important to note that due to insufficient data, this 
analysis only compared micro and small companies.  Therefore, it cannot be said with certainty 
that company size does not influence performance, as performance may significantly differ if 
micro and large companies were compared.   
5.6 Hypotheses 
5.6.1 Hypothesis 1 
Businesses with commitments to marketing and marketing strategy tend to outperform 
those without such commitments (Narver and Slater 1990).  This notion has been discussed by 
managers and studied by academics for decades (Narver and Slater 1990).  Narver and Slater’s 
(1990) MO instrument, designed to measure commitment to marketing and marketing strategy, 
has been used in various industries and cultural contexts, repeatedly lending support for its 
positive effect on performance (Appiah-Adu and Ranchhod 1998; Narver and Slater 1990; 
Subramanian and Gopalakrishna 2001; Deng and Dart 1994).  However, few empirical 
investigations explore MO and performance in the biotechnology industry (Appiah-Adu and 
Ranchhod 1998; De Luca, Verona, and Vicari 2010; Renko, Carsrud, and Brannback 2009).  
Furthermore, studies that have examined MO’s effect on performance in the biotechnology 
industry have produced contradictory findings, suggesting that MO may be somewhat contingent 
on the cultural context (Appiah-Adu and Ranchhod 1998; De Luca, Verona, and Vicari 2010; 
Renko, Carsrud, and Brannback 2009).     
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The first hypothesis envisaged that MO has a positive and significant effect on business 
performance.  Results showed that the independent variable MO had a positive and statistically 
significant effect on the dependent variable PERF (4.8.1 Market Orientation and Business 
Performance), thus supporting H1 (Figure 5.1).  
 
 
* p < 0.01 
Figure 5.1  Model 1 
Highly market-oriented Canadian medical/healthcare biotechnology companies achieved 
greater performance scores as compared to their lower market-oriented counterparts.  Companies 
that are committed to MO understand and create value for their target markets, recognize their 
competitors’ strengths, weaknesses, capabilities, and strategies, and disseminate information and 
share resources with other business units (Narver and Slater 1990).  The positive and statistically 
significant relationship between MO and PERF suggests that Canadian medical/healthcare 
biotechnology companies that understand their customers, acknowledge their competitors, and 
share knowledge with departments, outperform those that do not have such understandings or 
practices.  More broadly, organizations that are highly market-oriented possess an organizational 
culture that encourages behavioural commitments to marketing and marketing strategy (Narver 
and Slater 1990).  This commitment to marketing and marketing strategy among Canadian 
medical/healthcare companies leads to increased business performance.    
Support for H1 is consistent with the growing body of research that suggests MO affects 
business performance.  More specifically, it is congruent with the results from Appiah-Adu and 
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Ranchhod’s (1998) study of UK biotechnology companies and Renko, Carsrud, and Brannback’s 
(2009) findings related to Scandinavian human health biotechnology companies.  Appiah-Adu 
and Ranchhod (1998) confirmed that UK biotechnology companies committed to MO 
outperformed their competitors in terms of market share, profit margins, and overall 
performance.  Renko, Carsrud, and Brannback (2009) discussed how the relationship between 
MO and capital invested may be culturally dependent, as it was statistically significant among 
Scandinavian but not US human health biotechnology companies.  Moreover, De Luca, Verona, 
and Vicari (2010) found that of the three MO components, only interfunctional coordination was 
positively correlated with Italian biotechnology companies’ performance, providing further 
evidence that the strength of the MO and performance relationship may be culturally dependent. 
In summary, Canadian medical/healthcare biotechnology companies with high MO 
scores outperformed those with lower MO scores, providing support for the first hypothesis.  
However, a company’s commitment to MO does not solely necessitate strong business 
performance, thus the result of H1 should be interpreted with deliberation.  Echoing Appiah-Adu 
and Ranchhod (1998), although a positive relationship exists between MO and PERF, it is 
cautioned that other variables may influence PERF.  Neglecting to examine other variables may 
overstate or exaggerate MO’s importance (Appiah-Adu and Ranchhod 1998).  Appiah-Adu and 
Ranchhod (1998) suggest that future studies of MO in the biotechnology industry should 
consider a networking or alliance variable.  The following discussion of the second and third 
hypothesis address this concern. 
5.6.2 Hypothesis 2 
For over two decades, researchers have studied elements of strategic alliances and their 
effects on biotechnology business performance (Baum, Calabrese, and Silverman 2000; Baum 
and Silverman 2004; Forest and Martin 1992; George et al. 2001; George, Zahra, and Wood 
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2002; Silverman and Baum 2002; Sarkar, Echambadi, and Harrison 2001; Standing, Standing, 
and Lin 2008).  Until now, no known study has measured strategic alliance management 
comprehensively and examined its effect on business performance in the biotechnology industry.   
The second hypothesis envisaged that AO has a positive and significant effect on 
business performance.  Results showed that the independent variable AO had a positive and 
statistically significant effect on the dependent variable PERF (4.8.2 Alliance Orientation and 
Business Performance), thus supporting H2 (Figure 5.2). 
 
 
** p < 0.001 
Figure 5.2  Model 2 
Highly alliance-oriented Canadian medical/healthcare biotechnology companies achieved 
greater performance scores as compared to their lower alliance-oriented counterparts.  
Companies that are alliance-oriented acquire, interpret, and leverage strategic alliance 
management knowledge throughout their organizations (Kandermir, Yaprak, and Cavusgil 
2006).  The positive and statistically significant relationship between AO and PERF suggests that 
Canadian medical/healthcare biotechnology companies that monitor their environment for new 
partnering opportunities, engage in strategy development and knowledge sharing with their 
existing alliance partners, and disseminate new knowledge with their partners, outperform those 
that do not participate in such activities.  More simply, companies that are highly alliance-
oriented engage in a multitude of strategic alliance management activities with its partners 
(Kandermir, Yaprak, and Cavusgil 2006).  This engagement in strategic alliance management 
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activities by Canadian medical/healthcare biotechnology companies appears to lead to increased 
business performance. 
Support for H2 is consistent with the results from Kandermir, Yaprak, and Cavusgil’s 
(2006) study of US technology companies and the large body of research that suggests strategic 
alliance management practices increase biotechnology business performance (Baum, Calabrese, 
and Silverman 2000; Baum and Silverman 2004; Forest and Martin 1992; George et al. 2001; 
Sarkar, Echambadi, and Harrison 2001).  Kandermir, Yaprak, and Cavusgil (2006) found high 
AO resulted in strengthened performance among US technology companies.  Although no 
known study of biotechnology companies has utilized the AO instrument, previous findings have 
supported Kandermir, Yaprak, and Cavusgil’s (2006) three AO components.  Specifically, 
Sarkar, Echambadi, and Harrison’s (2001) found that biotechnology companies’ proactive 
activities to obtain alliances positively affects performance, supporting the alliance scanning 
component.  Baum, Calabrese, and Silverman (2000) found that securing partnerships at specific 
development stages increased biotechnology companies’ performance, resembling the alliance 
coordination component.  Forest and Martin (1992) emphasized that benefits from strategic 
alliances in the biotechnology industry do not come without a considerable amount of energy and 
commitment, validating the alliance learning component.  
To reiterate, Canadian medical/healthcare biotechnology companies with high AO scores 
outperformed those with lower AO scores, providing support for the second hypothesis.  As with 
the result of the first hypothesis, a company’s commitment to AO does not solely perpetuate high 
business performance, thus the result of H2 should also be interpreted with caution.   
5.6.3 Hypothesis 3 
Marketing and strategic alliance management competencies have been cited as critical to 
the success of biotechnology companies (Hourd and Williams 2008; Yim and Weston 2007).  
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Previous studies of biotechnology companies found that the relationship between MO and 
performance was positive and significant (Appiah-Adu and Ranchhod 1998; Renko, Carsrud, 
and Brannback 2009).  The finding from the first hypothesis confirmed that Canadian 
medical/healthcare biotechnology companies with high MO scores outperformed companies 
without such scores.  Strategic alliance management competencies have been shown to increase 
the performance of biotechnology companies (Baum, Calabrese, and Silverman 2000; Baum and 
Silverman 2004; Forest and Martin 1992; George et al. 2001; Sarkar, Echambadi, and Harrison 
2001).  The finding from the second hypothesis confirmed that Canadian medical/healthcare 
biotechnology companies with high AO scores outperformed companies without such scores.   
The third hypothesis envisaged that MO and AO has a positive and significant additive 
effect on business performance.  The results showed that AO had a positive and statistically 
significant effect, but MO had a non-significant effect, on PERF (4.8.3 Market Orientation, 
Alliance Orientation, and Business Performance), thus only partially supporting H3.  Originally, 
MO had a statistically significant influence on PERF as the sole predictor in the model (Figure 
5.1), but its influence became non-significant as AO entered the model (Figure 5.3).  
 
 
** p < 0.001 
Figure 5.3  Model 3 
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This phenomenon (Figure 5.3) resembles the mediation relationship described by Baron 
and Kenny (1986).  Accordingly, a fourth regression analysis was performed using the non-
significant predictor (MO) as the independent variable and the statistically significant predictor 
(AO) as the dependent variable.  The relationship between MO and AO was positive and 
statistically significant (4.8.4 Market Orientation and Alliance Orientation), thus supporting the 
existence of a mediation relationship (Figure 5.4). 
 
 
** p < 0.001 
Figure 5.4  Model 4 
  MO’s effect on PERF is fully mediated by AO.  The mediation relationship suggests 
that MO influences AO which in turn influences PERF.  Medical/healthcare biotechnology 
companies with high MO scores achieved higher AO scores, and the higher AO scores resulted 
in increased PERF scores.   
“Market orientation is the organizational culture that most effectively and efficiently 
creates the necessary behaviors for the creation of superior value for buyers and, thus, continuous 
superior performance for the business” (Narver and Slater 1990, 21).  MO is an organizational 
culture that encourages customer-oriented, competitor-oriented, and interfunctionally-
coordinated behaviours.  AO is a comprised of three organizational capabilities including 
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alliance scanning, alliance coordination, and alliance learning (Kandermir, Yaprak, and Cavusgil 
2006).  “Alliance orientation will be strong when a firm possesses higher degrees of each of 
these capabilities and is able to skillfully configure and deploy them” (Kandermir, Yaprak, and 
Cavusgil 2006, 326).  In the case of Canadian medical/healthcare biotechnology companies, 
perhaps MO is the foundation and AO is the vehicle for increasing PERF.  Consequently, 
companies that encourage organizational behaviours including customer orientation, competitor 
orientation, and interfuctional coordination may be better equipped to engage in alliance 
scanning, alliance coordination, and alliance learning activities.  Ultimately, it is the successful 
execution of these alliance activities that appears to increase business performance.   
The Canadian medical/healthcare biotechnology industry has embraced Narver and 
Slater’s (1990) market-oriented organizational culture, as companies in the industry understand 
their target markets and customers, recognize their competitors’ strengths and weaknesses, and 
disseminate knowledge throughout their departments.  Having this market-oriented 
organizational culture is necessary for, but does not directly influence, performance.  Canadian 
medical/healthcare companies have adopted Kandermir, Yaprak, and Cavusgil’s (2006) alliance-
oriented organizational capabilities, as companies actively scan for new alliance partners, 
effectively manage existing alliances, and learn from its partners.  The alliance management 
organizational capabilities act as catalyst that enable the realization of the full benefits of a 
market-oriented organizational culture.   
5.6.4 Post-Hoc Analyses 
Overall, the findings from the post-hoc regression analyses that included control variables 
were similar to the previous findings from the regression analyses that did not include control 
variables.  Therefore, the findings from the post-hoc regression analyses supported the notion 
that MO is fully mediated by AO in its relationship with PERF.  Ultimately, a sequential 
 84 
relationship exists among MO, AO, and PERF, as a business’ philosophy needs to be established 
prior to its undertaking of activities, and the execution of those practices, grounded in the 
organizational philosophy, perpetuates business performance. 
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CHAPTER 6 
LIMITATIONS 
The first limitation of this study was the response rate.  Although this study compared 
favourably to similar studies in terms of the number of responses received (N = 81), the response 
rate was comparatively lower (20.6%).  Appiah-Adu and Ranchhod (1998) received a response 
rate of 58.5 percent (62/106) and Renko, Carsrud, and Brannback received a response rate of 
44.3 percent (85/192).  Although De Luca, Veona, and Vicari (2010) reported a response rate of 
53.4 percent, they actually received a response rate of 42.9 percent (70/163).  Low response rates 
can give rise to issues related to biases, power, and generalizability.  In the absence of a non-
responder questionnaire, non-response bias was tested by comparing key constructs (MO, AO, 
and PERF) among early and late responders.  Results showed no differences in the mean MO, 
AO, and PERF scores, thus not supporting the existence of a non-response bias.  However, these 
post-hoc tests only provide support to move forward with other analyses and do not remedy the 
issue at large (Zhang 2008).  Despite this study’s low response rate, all regression analyses 
achieved acceptable power (1-β ≥ 0.80).  However, the fact remains that a large number of 
Canadian medical/healthcare companies did not respond to the questionnaire, limiting the 
generalizability of the findings.   
The timing of the study may have negatively impacted the response rate.  Specifically, 
data collection was conducted over the summer months, beginning in late May and ending in late 
August.  It is possible that some executives were on holiday during the time of data collection.  
Accounting for this assumption, the first measure taken to increase the response rate was to 
extend data collection beyond the conventional time frame.  Contacting BIOTECanada, the 
Canadian national biotechnology association, for an endorsement was the second measure taken 
in an attempt to increase the response rate.  Obtaining an endorsement from an organization or 
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individual that is apart of executives’ social networks has been shown to increase response rates 
(Bednar and Westphal 2006; Bartholomew and Smith 2006; Cycyota and Harrison 2006; 
Rochford and Venable 1995).  The inability to secure an endorsement from BIOTECanada may 
have negatively impacted the response rate.  However, it became apparent that securing an 
endorsement from BIOTECanada is beyond the control of any researcher.  BIOTECanada’s 
organizational policies prohibit it from officially supporting any study that itself does not 
commission.  Collaboration with UQAM was the third measure taken to increase the response 
rate.  As discussed, UQAM’s support was sought to help legitimize the study within the French-
speaking business community.  The final measure taken to increase the response rate was the 
employment of a multi-modal study, giving respondents two completion options.  While only 20 
online responses were received, neglecting to employ a multi-modal study could have resulted in 
fewer responses.  Despite the measures taken, the response rate is still of concern and a 
fundamental limitation of the study. 
The next limitation was a result of the multi-modal approach.  Specifically, employing a 
multi-modal survey can introduce additional biases.  Formerly, it was cautioned that Internet 
users and non-users were distinctly different and that data received online may be biased toward 
technologically savvy respondents (Ilieva, Baron, and Healey 2002).  In recent years due to the 
growth in the number of Internet users, this problem has lessened (Ilieva, Baron, and Healey 
2002).  Additionally, seeing as this study was conducted in an industry that is at the forefront of 
technological innovation, the issue is of even less concern.  Nevertheless, key constructs (MO, 
AO, and PERF) among mail and online responders were compared, resulting in no statistically 
significant differences in mean scores.  Although these post-hoc tests enable researchers to 
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perform further analyses, they do not resolve issues (Zhang 2008).  Thus, the issue of biases 
related to the multi-modal approach remains a limitation of the study.  
Another limitation of this study is the single-respondent approach, as one respondent per 
company answered questions related to marketing, alliance management, and performance.  It 
has been shown that senior-level managers have been more reliable than other employees when it 
comes to providing organizational information (Phillips 1981).  In an attempt to reduce the 
single-respondent bias, CEOs were asked to complete the questionnaires.  Notwithstanding, the 
single-respondent bias still remains a limitation of this study. 
The final limitation of the study is the scope and nature of the investigation.  This study 
investigated the importance of marketing and strategic alliances in determining business 
performance, a topic that was salient to the researcher.  The hypothesized antecedents were 
generated from literature and guided by the researcher’s knowledge and interests.  Although the 
genesis of most inquiries is a result of a researcher’s interest, it is important to note the 
researcher’s influence.  
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CHAPTER 7 
CONCLUSION & FUTURE DIRECTIONS 
Empirical data from this study lends support for the importance of market and alliance 
orientation in determining Canadian medical/healthcare biotechnology companies’ performance.  
The relationship between MO and PERF was positive and statistically significant, suggesting 
MO was an antecedent to PERF.  The relationship between AO and PERF was also positive and 
statistically significant, suggesting that AO was an antecedent to PERF.  When MO and AO 
were examined together, MO became non-significant, while AO remained a statistically 
significant predictor of PERF.  This phenomenon prompted further analyses that examined the 
relationship between MO and AO.  The relationship between MO and AO was positive and 
statistically significant, supporting the existence of a mediation relationship.  Specifically, MO’s 
influence on PERF was found to be fully mediated by AO.  In post-hoc analyses, that included 
the aforementioned control variables, these regression analyses were repeated.  The post-hoc 
regression results supported the notion that MO’s influence on PERF was fully mediated by AO.  
Due to the slight increase in R2, as a result of the inclusion of the control variables, future 
research could investigate these control variables with a more robust sample size. 
The findings from the first set of additional analyses provided no evidence to suggest MO 
or AO scores differed based on the response language.  However, it was found that PERF scores 
differed based on response language.  The second set of additional analyses provided no 
evidence to suggest MO, AO, or PERF differed based on completion method.  The findings from 
the third set of additional analyses provided no evidence to suggest MO, AO, or PERF scores 
differed based on companies’ geographical locations.  The results from the fourth set of 
additional analyses indicated that the number of association memberships companies held did not 
influence their MO, AO, or PERF scores.  The results of the fifth set of additional analyses 
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suggested that privately owned companies were more market-oriented than publicly traded 
companies.  The results of the sixth set of additional analyses provided no evidence to suggest 
that companies’ MO, AO, or PERF scores differed based on the educational backgrounds of their 
CEOs.  The results of the seventh set of additional analyses suggested that the age of companies 
did not influence their MO or AO scores.  However, it was found that the age of companies had a 
negative statistically significant effect on PERF.  The findings from the final set of additional 
analyses provided no evidence to suggest MO, AO, or PERF scores differed based companies’ 
size.  
The findings from this study have several implications for biotechnology entrepreneurs 
and managers.  First, the results provide evidence that behavioural orientations toward 
customers, competitors, and business units are the foundation needed to increase business 
performance.  The findings also indicate that managers should pay particular attention to alliance 
scanning, coordinating, and learning, as these activities enable business performance.  Third, 
managers should understand the sequential relationship between the market-oriented behavioural 
commitments, alliance-oriented activities, and business performance outcomes, as it can aid in 
business development.  For instance, the sequential relationship between these behaviours, 
activities, and outcomes can act as a theoretical pathway to increase performance.  Companies 
that were highly market-oriented were also highly alliance-oriented, and highly alliance-oriented 
companies were top performing companies.  The apparent sequential relationship is not the only 
commercialization pathway, nor does it explain all of the behaviours and activities needed to be 
commercially successful, but it is important for managers and entrepreneurs to be mindful of its 
significance.  Finally, results provided no evidence to suggest that companies’ MO, AO, or 
PERF scores differed based on the educational backgrounds of their CEOs.  It was deduced that 
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CEOs with specific skill sets likely surround themselves with individuals with complementary 
competencies.  This delineates the final managerial implication that managers and entrepreneurs 
should surround themselves with individuals who have complementary experience, knowledge, 
and skills.   
These findings produced several contributions to marketing and management academic 
research.  First, Narver and Slater’s (1990) MO instrument proved to be successful with an 
unstudied population.  The instrument’s success in the Canadian medical/healthcare 
biotechnology industry contributed to a large body of research that confirms MO positively 
influences performance.  Second, this was the first known study to comprehensively measure 
strategic alliance management activities in the biotechnology industry.  This study employed the 
underutilized Kandermir, Yaprak, and Cavusgil (2006) AO instrument, thereby expanding AO 
research and the use of the instrument.  Moreover, the findings contribute to a large body of 
research that suggests strategic alliance management positively influences biotechnology 
performance.  Third, this study goes beyond confirming MO and AO’s importance in the 
relationship with PERF, as the existence of a mediation relationship was tested and confirmed.  
Fourth, and perhaps the most significant contribution was the development and successful use of 
the PERF instrument.  The PERF instrument proved to be an effective instrument when 
measuring biotechnology business performance.  Finally, the findings expand the scope of 
biotechnology marketing and strategic alliance management research.  It may be fruitful to 
explore MO in other biotechnology subsectors, expand the use of the AO instrument in other 
industries and cultural contexts, utilize the newly developed and successful PERF instrument to 
measure biotechnology performance in other subsectors and cultural contexts, and investigate the 
influence of other possible antecedents to biotechnology business performance.
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1. Please specify the main operating sector of your biotechnology company: 
Medical/Healthcare 
(Human-Focused) 
Medical/Healthcare 
(Animal-Focused) 
Agriculture/ 
Food 
Environmental/ 
Industrial 
Information 
Technology 
Other 
     __________ 
          Does you company have the potential to become human-focused?  
 
 
Please check the most appropriate box when answering these questions about your company’s position in the 
industry: 
 
2. Our business objectives are driven primarily by customer satisfaction: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
3. Our strategy for competitive advantage is based on our understanding of customers’ needs: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
4. Our business strategies are driven by our beliefs about how we can create greater value for customers: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
5. We measure customer satisfaction systematically and frequently: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
6. All business functions (e.g. marketing/sales, manufacturing, R&D, finance/accounting, etc.) share information 
concerning competitors’ strategies: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
7. We rapidly respond to competitive actions that threaten us: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
8. Top managers regularly discuss competitors’ strengths and strategies: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
 
Yes   No   
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9. We target customers where we have an opportunity for competitive advantage: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
10. We freely communicate information about our successful and unsuccessful customer experiences across all business 
functions: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
11. All business functions are integrated in serving the needs of our target markets: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
12. All business functions understand how everyone in our business can contribute to creating customer value: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
13. We share resources with other business units: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
Please check the most appropriate box when answering these questions about your company’s partnerships: 
 
14. We actively monitor our environment to identify partnering opportunities: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
15. We routinely gather information about prospective partners from various forums (e.g. trade shows, industry conventions, 
databases, publications, internet, etc.):  
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
16. We are alert to market developments that create potential alliance opportunities: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
17. Our activities across different alliances are well coordinated: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
 
 
 
 
 
 105 
18. We systematically coordinate our strategies across different alliances: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
19. We have processes to systematically transfer knowledge across alliance partners: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
20. We conduct periodic reviews of our alliances to understand what we are doing right and where we are going wrong: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
21. We periodically collect and analyze field experiences from our alliances: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
22. We modify our alliance-related procedures as we learn from experience: 
 
Strongly Disagree Disagree Neutral Agree Strongly Agree 
     
 
Based on the last three years, please indicate the extent that your company has achieved its stated objectives in terms 
of: 
 
23. Generation of new innovative products or projects: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
24. New patents: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
25. Quality and relevance of scientific output: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
26. Attainment of scientific results or milestones: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
27. Recruitment of new personnel with outstanding knowledge and skills: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
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28. Scientific or technological leadership in your environment: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
29. Attainment of new capital, either public or private: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
30. Maintenance and generation of alliances or partnerships: 
 
To No Extent To A Small Extent To A Moderate 
Extent 
To A Considerable 
Extent 
To A Great Extent 
     
 
Please answer the following general descriptive questions:  
 
31. Is your company headquartered in Canada? 
 
32. Is your company located in a biotechnology or science park?  
 
 
33. If the answer to Question 32 was yes, please state the park’s name  _________________________ 
34. Please indicate if your company is affiliated with any of the following associations: 
 
 BIOTECanada  BioAtlantech  BioNova   Genome Canada 
 OCRI Life 
Sciences 
 Toronto Biotechnology Institute 
 
 MaRS Discovery 
District 
 Pharmabio 
Development 
 BioQuebec  Parc Technologique du Quebec 
Metropolitain 
 Canadian Genetic 
Diseases Network 
 Alberta Research 
Council 
 BioAlberta  LifeScience Association of Manitoba  British Columbia 
Life Sciences 
 Prince Edward 
Island BioAlliance 
 Ag-West Bio Inc.  Biotechnology Industry Association  Newfoundland and Labrador Association of 
Technology Industries 
 BioTalent Canada  Other  _____________________    
 
35. What is your company’s ownership structure? 
Privately Owned Publicly Traded Subsidiary Government Other 
    _______________ 
36. What is the CEO or President’s educational background? __________________ 
 
37. What year was your company founded? __________________ 
 
38. How many individuals does your company employ? __________________ 
 
39. What are the first three letters of your company’s postal code? __________________ 
 
Please provide any additional comments, suggestions, or concerns in the section below:  
 
Yes   No   
Yes   No   
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The portion below will be separated from the above questionnaire before any responses are put into a database so that your 
responses are not identifiable by any information provided below. 
 
 
 
Once the responses from this survey have been compiled and analyzed, would you like to receive a summary of the findings? 
 
  Yes via e-mail  
(please provide e-mail address)  
  Yes via postal mail  
(please provide postal address)  
 
 
Thank you for participating in this study – your time and willingness to participate is greatly appreciated! 
  
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1. Veuillez s'il vous plaît spécifier le secteur d'exploitation principal de votre société de biotechnologie : 
Médical/Santé 
(Concentrée sur 
l’humain) 
Médical/Santé 
(Concentrée sur les 
animaux) 
Agriculture/ 
Alimentation 
Environment/ 
Industriel 
Technologie 
de 
l’information 
Autre 
     __________ 
        Votre compagnie a-t-elle le potentiel de développer la concentration humaine?  
 
 
Veuillez s’il-vous-plaît cocher la case la plus appropriée en répondant aux prochaines questions concernant la position 
de votre compagnie dans l’industrie: 
 
2. Nos objectifs d’entreprise sont principalement dirigés vers la satisfaction de nos clients : 
  
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
3. Notre stratégie pour avoir un avantage concurrentiel est basée sur notre compréhension des besoins de nos clients: 
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
4. Nos stratégies d’affaires sont conduites par nos convictions concernant la façon dont nous pouvons créer plus de valeur 
pour nos clients:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
5. Nous mesurons systématiquement et fréquemment la satisfaction de nos clients:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
6. Toutes les fonctions de l’entreprise partagent de l’information concernant les stratégies des concurrents:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
7. Nous répondons rapidement aux actions concurrentielles qui nous menacent:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
8. La haute direction discute régulièrement des forces et des stratégies de concurrents :  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
Oui   Non   
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9. Nous ciblons les clients pour lesquels nous avons l’occasion d’avoir un avantage concurrentiel:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
10. Nous communiquons librement l’information concernant nos succès et nos expériences clients infructueuses au sein de 
toutes les fonctions de l’entreprise:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
11. Toutes les fonctions de l’entreprise (ex.: marketing/ventes, fabrication, R&D, finance/comptabilité, etc.) sont intégrées 
pour répondre aux besoins de nos marchés cibles.  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
12. Toutes les fonctions de l’entreprise comprennent que chaque personne de l’entreprise est impliquée dans la création de 
valeur pour le client 
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
13. Nous partageons des ressources avec d’autres unités d’affaire: 
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
Veuillez s’il-vous-plaît cocher la case la plus appropriée en répondant aux prochaines questions concernant les 
partenariats de votre entreprise : 
 
14. Nous surveillons activement notre environnement afin d’identifier les occasions de partenariats:  
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
15. Nous recueillons régulièrement de l’information concernant les partenaires potentiels par divers moyens (salons 
professionnels, conventions de l’industrie, bases de données, publications, internet, etc.) :  
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
16. Nous sommes alertes aux développements dans le marché qui créent des occasions d’alliances potentielles:  
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
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17. Nos activités à travers les différentes alliances sont bien coordonnées:  
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
18. Nous coordonnons systématiquement nos stratégies à travers différentes alliances:  
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
19. Nous avons des processus pour systématiquement transférer la connaissance à travers les partenaires d’alliances :  
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
20. Nous conduisons des évaluations périodiques de nos alliances pour comprendre ce que nous faisons bien et ce que nous 
faisons mal:  
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
21. Nous collectons et analysons périodiquement des données issues d’expériences menées par nos partenaires : 
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
22. Nous modifions nos procédures liées à nos alliances selon ce que nous apprenons avec l’expérience:   
 
Fortement en 
désaccord 
En désaccord Neutre En accord  Fortement en accord 
     
 
Sur la base des trois dernières années, veuillez indiquer dans quelle mesure votre compagnie a atteint les objectifs 
fixés en terme de:   
 
23. Génération de nouveaux produits ou projets innovants: 
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
24. Nouveaux brevets: 
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
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25. Qualité et pertinence de la production scientifique (scientific output): 
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
26. Atteinte des résultats scientifiques ou d’étapes scientifique importantes (milestones): 
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
  
27. Recrutement de personnel avec d’excellentes compétences et connaissances:   
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
28. Leadership scientifique ou technologique dans votre environnement:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
29. Acquisition de nouveau capital, qu’il soit public ou privé:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
30. Maintient et génération d’alliances ou de partenariats:  
 
Aucunement Dans une faible 
mesure 
Moyennement Dans une forte 
mesure 
Dans une très forte 
mesure 
     
 
Veuillez s’ils-vous-plaît répondre aux questions descriptives générales suivantes:  
 
31. Le siège social de votre compagnie est-il au Canada? 
 
32. Votre compagnie est-elle située dans un parc de recherche ou un technopôle  ?  
 
 
33. Si la réponse à la question 32 est oui, veuillez indiquer le nom du parc : _________________________ 
34. Veuillez indiquer si votre compagnie est affiliée avec une des associations suivantes:  
 
 BIOTECanada  BioAtlantech  BioNova   Genome Canada 
 OCRI Life 
Sciences 
 Toronto Biotechnology Institute 
 
 MaRS Discovery 
District 
 Pharmabio 
Development 
 BioQuebec  Parc Technologique du Québec  Genetic Diseases  Alberta Research 
Oui   Non   
Oui   Non   
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Métropolitain Network Council 
 BioAlberta  LifeScience Association of Manitoba  British Columbia 
Life Sciences 
 Prince Edward 
Island BioAlliance 
 Ag-West Bio Inc.  Biotechnology Industry Association  Newfoundland and Labrador Association of 
Technology Industries 
 BioTalent Canada  Autre  _____________________    
 
35. Quelle est la structure de propriété de votre compagnie? 
Privée Société cotée en 
bourse 
Filiale Organisation 
gouvernementale 
Autre 
    _______________ 
36. Quel est le niveau d’étude du Président ou PDG? __________________ 
 
37. En quelle année votre compagnie a-t-elle été créée? __________________ 
 
38. Combien d’employés votre compagnie compte-t-elle? __________________ 
 
39. Quelles sont les 3 premiers caractères du code postal de votre compagnie? __________________ 
 
Veuillez s’il-vous-plaît fournir tout commentaire, suggestion ou préoccupation dans la section ci-dessous:  
 
 
 
La portion ci-dessous sera séparée du reste du questionnaire avant que les réponses ne soient mises dans une base de données 
afin que vos réponses ne soient pas identifiables par aucune des informations fournies ci-dessous.  
 
 
 
Une fois les réponses à ce sondage compilées et analysées, désireriez-vous recevoir un sommaire des résultats?  
 
  Oui par courriel  
(S’il-vous-plaît fournir votre adresse 
courriel) 
 
  Oui par la poste  
(S’ils-vous-plaît fournir votre adresse 
postale) 
 
 
 
Merci d’avoir participé à cette étude – Votre temps et votre volonté à participer sont grandement appréciés!  
  
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APPENDIX C 
Market Orientation (Adapted) – Narver and Slater (1990) 
 
Customer Orientation 
1. Our business objectives are driven primarily by customer satisfaction. 
2. Our strategy for competitive advantage is based on our understanding of customers’  
needs. 
3. Our business strategies are driven by our beliefs about how we can create greater value  
for customers. 
4. We measure customer satisfaction systematically and frequently. 
Competitor Orientation 
5. All business functions share information concerning competitors’ strategies. 
6. We rapidly respond to competitive actions that threaten us. 
7. Top managers regularly discuss competitors’ strengths and strategies. 
8. We target customers where we have an opportunity for competitive advantage. 
Interfunctional Coordination 
9. We freely communicate information about our success and unsuccessful customer  
experiences across all business functions. 
10. All business functions (e.g. marketing/sales, manufacturing, R&D, finance/accounting,  
etc.) are integrated in serving the needs of our target markets.  
11. All business functions understand how everyone in our business can contribute to  
creating customer value. 
12. We share resources with other business units. 
 
 
NOTES:  1 = to no extent, 2 = to a small extent, 3 = to a moderate extent, 4 = to a considerable 
extent, 5 = to a great extent. 
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APPENDIX D 
Alliance Orientation – Kandemir, Yaprak, Cavusgil (2006)  
 
Alliance Scanning 
1. We actively monitor our environment to identify partnering opportunities. 
2. We routinely gather information about prospective partners from various forums (e.g.   
trade shows, industry conventions, databases, publications, internet, etc.) 
3. We are alert to market developments that create potential alliance opportunities. 
Alliance Coordination 
4. Our activities across different alliances are well coordinated. 
5. We systematically coordinate our strategies across different alliances. 
6. We have processes to systematically transfer knowledge across alliance partners. 
Alliance Learning 
7. We conduct periodic reviews of our alliances to understand what we are doing right and  
what we are doing wrong. 
8. We periodically collect and analyze field experiences from our alliances. 
9. We modify our alliance related procedures as we learn from experience. 
 
 
NOTES:  1 = strongly disagree; 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree.  
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APPENDIX E 
R&D Effectiveness – De Luca, Verona, and Vicari (2010) 
 
Rate the extent to which in the last three years your company’s R&D has achieved its stated 
objectives in terms of: 
1. Generation of new innovative projects. 
2. New patents. 
3. Quality and relevance of scientific output. 
4. Industry reputation for scientific results. 
5. Generation of new knowledge on target technology/market domains. 
6. Ability to attract and recruit new scientist with outstanding knowledge and skills. 
7. Scientific/technological leadership in your environment. 
 
NOTES:  1 = to no extent; 7 = to a great extent. 
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APPENDIX F 
Business Performance 
R&D Effectiveness (Adapted and Broadened) – De Luca, Verona, and Vicari (2010) 
 
Rate the extent to which in the last three years your company has achieved its stated 
performance objectives in terms of: 
1. Generation of new innovative products or projects. 
2. New patents. 
3. Quality and relevance of scientific output. 
4. Attainment of scientific results or milestones. 
5. Recruitment of new personnel with outstanding knowledge and skills. 
6. Scientific or technological leadership in your environment. 
7. Attainment of new capital, either public or private. 
8. Maintenance and generation of alliances or partnerships. 
 
NOTES:  1 = to no extent, 2 = to a small extent, 3 = to a moderate extent, 4 = to a considerable 
extent, 5 = to a great extent. 
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APPENDIX G 
 
 
May 28, 2012 
 
«Title»«First_Name»«Last_Name» 
«Company» 
«Address» 
«City», «Province»  «Postal_Code» 
 
RE: Business Practices of Canadian Biotechnology Companies 
 
Dear «Title»«Last_Name», 
 
This study seeks to enhance our understanding of the current business practices of Canadian 
biotechnology companies.  The questionnaire we are asking you to complete, should take roughly 10 
minutes.  The questionnaire can be completed by mail and returned in the pre-stamped envelope 
provided, or online by visiting https://survey.qualtrics.com/SE/?SID=SV_5hFkveDPwEF0HxW and 
entering your identification code («CODE»).  Your participation is important and we look forward to 
receiving your completed questionnaire.  As a token of our appreciation for your participation, if you 
would like, the information obtained from you and other participants in the study will be aggregated 
and sent to your organization. 
 
Your participation is important.  However, it is completely voluntary and you do not have to complete 
the questionnaire.  You may also refuse to answer individual questions and you may withdraw from 
the study at anytime.  The code number on the questionnaire is designed to give the investigators the 
ability to track responses while keeping your identity strictly confidential.  Once the data collection is 
complete, the list that links code numbers to names will be destroyed.  Only the principal investigator 
(Jason Perepelkin) and co-investigator (Grant Wilson) will have access to the data arising from the 
study.  All information will be stored in secure, locked facilities in the office of the principal 
investigator (Jason Perepelkin) at the University of Saskatchewan.  Results will be aggregated to 
ensure that the identities of individual respondents are safeguarded.  Results will be reported in the 
student-researcher’s Thesis, refereed periodicals, and at conferences and meetings associated with 
biotechnology, pharmaceutical, and business research. 
 
Should you have any concerns about this research project do not hesitate to contact the principal 
investigator (Jason Perepelkin) by e-mail (jason.perepelkin@usask.ca), phone (306-966-6992), or 
facsimile (306-966-6377).  You completing this questionnaire, either by mail or online, constitutes 
consent for the researchers to use the data for the purpose of conducting the study, as this study has 
received exempt status from the University of Saskatchewan Behavioural Research Ethics Board 
(BEH 120-104, April 9, 2012).  Should you have any questions regarding your rights as a participant 
in this study you may call the Ethics Office at the University of Saskatchewan (306-966-2084).  Out 
of town participants may call collect. 
 
Sincerely, 
 
     
Grant Wilson, BComm 
MSc Candidate 
University of Saskatchewan 
 
 Jason Perepelkin, PhD 
Assistant Professor 
University of Saskatchewan 
 Marc-Antoine Vachon, PhD Candidate 
Professor, Department of Marketing 
ESG-UQAM 
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APPENDIX H 
 
 
 
28 mai 2012 
 
«Title»«First_Name»«Last_Name» 
«Company» 
«Address» 
«City», «Province»  «Postal_Code» 
 
Objet: Les pratiques commerciales des entreprises canadiennes en biotechnologie 
 
Bonjour «Title»«Last_Name», 
 
Cette étude cherche à améliorer notre compréhension des pratiques commerciales actuelles des entreprises 
canadiennes en biotechnologie. Le questionnaire que nous vous demandons de compléter devrait prendre 
environ 10 minutes. Le questionnaire peut être envoyé par la poste et retourné avec l’enveloppe 
préaffranchie fournie, ou en ligne au https://survey.qualtrics.com/SE/?SID=SV_1YeyyTUzqDZ9FYw en 
entrant votre code d’identification («CODE»). Votre participation est importante et nous espérons 
fortement recevoir votre questionnaire rempli. En gage de notre appréciation, si vous le désirez, les 
informations obtenues durant l’étude auprès des autres participants et vous seront agrégées puis envoyées à 
votre organisation.  
 
Votre participation est importante. Toutefois, elle est complètement volontaire et vous n’êtes pas tenu de 
compléter le questionnaire. Vous pouvez également refuser de répondre aux questions individuelles et vous 
pouvez vous retirer de l’étude à tout moment. Le code numérique sur le questionnaire est conçu pour 
donner aux enquêteurs la possibilité de suivre les réponses tout en gardant votre identité strictement 
confidentielle. Une fois la collecte de donnée terminée, la liste liant les codes numériques aux noms sera 
détruite. Seul le chercheur principal (Jason Perepelkin) et le co-chercheur (Grant Wilson) auront accès aux 
données découlant de l’étude. Toutes les informations seront conservées dans des installations sécurisées 
sous verrou dans le bureau du chercheur principal (Jason Perepelkin) à l’Université de Saskatchewan. Les 
résultats seront regroupés pour assurer la protection de l’identité des répondants. Les résultats seront 
présentés dans la thèse de l'étudiant-chercheur, dans des revues scientifiques, et lors de conférences et 
réunions liées à la biotechnologie, à la pharmaceutique, et à la recherche commerciale. 
 
Si vous avez des préoccupations concernant ce projet de recherche, n’hésitez pas à contacter le chercheur 
principal (Jason Perepelkin) par courriel (jason.perepelkin@usask.ca), par téléphone (306-966-6992), ou 
par télécopieur (306-966-6377). En remplissant ce questionnaire, par courrier ou en ligne, vous donnez 
votre consentement aux chercheurs pour qu’ils utilisent les données dans le but de conduire l’étude, tel 
qu’approuvé par le comité sur l’éthique en recherche comportementale de l’Université de Saskatchewan 
(BEH 120-104, 9 avril 2012). Si vous avez des questions quant à vos droits comme participant à cette 
étude, vous pouvez appeler le Bureau de l'éthique à l'Université de Saskatchewan (306-966-2084). Les 
participants hors région peuvent effectuer des appels à frais virés.  
 
Sincèrement, 
 
     
Grant Wilson, BComm 
Candidat à la MSc 
Université de Saskatchewan 
 
 Jason Perepelkin, PhD 
Professeur adjoint 
Université de Saskatchewan 
 
 Marc-Antoine Vachon, candidat au PhD 
Professeur  
Département de marketing  
ESG-UQAM 
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APPENDIX I 
 
 
RE: Business Practices of Canadian Biotechnology Companies 
 
You recently received a request to complete a questionnaire on your company’s current business practices.  If you have already 
completed the questionnaire online or have already returned it via mail, thank you.  If you have not yet completed the questionnaire 
and intend to do so, we would ask that you complete it as soon as possible and return it in the pre-stamped envelope provided or visit 
https://survey.qualtrics.com/SE/?SID=SV_5hFkveDPwEF0HxW and enter your identification code.   
 
As you know, the purpose of this study is to understand the current business practices of Canadian biotechnology companies.  As a 
token of our appreciation for your participation, the information obtained from you and other participants in the study will be 
aggregated and sent to your organization. 
 
Your participation is important.  However, it is completely voluntary and you do not have to complete the questionnaire.  You may 
also refuse to answer individual questions and you may withdraw from the study at anytime.  Should you have any concerns about this 
research project do not hesitate to contact the principal investigator (Jason Perepelkin) by e-mail (jason.perepelkin@usask.ca), phone 
(306-966-6992), or facsimile (306-966-6377).  
 
Sincerely,  
 
     
Grant Wilson, BComm 
MSc Candidate 
University of Saskatchewan 
 
 Jason Perepelkin, PhD 
Assistant Professor 
University of Saskatchewan 
 Marc-Antoine Vachon, PhD Candidate 
Professor, Department of Marketing 
ESG-UQAM 
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Objet: Les pratiques commerciales des entreprises canadiennes en biotechnologie 
 
Vous avez récemment reçu une demande pour répondre à un questionnaire concernant les pratiques commerciales actuelles de votre 
entreprise. Si vous avez déjà rempli le questionnaire en ligne ou l’avez déjà acheminé par la poste, merci. Si vous n’avez pas rempli le 
questionnaire mais vous avez l’intention de le faire, nous vous demanderions de le remplir le plus tôt possible et de le retourner avec 
l’enveloppe préaffranchie, ou d’accéder au https://survey.qualtrics.com/SE/?SID=SV_1YeyyTUzqDZ9FYw et d’entrer votre code 
d’identification. 
 
Comme vous le savez, l’objectif de cette étude est de comprendre quelles sont les pratiques commerciales actuelles des entreprises 
canadiennes en biotechnologie. En gage de notre appréciation, si vous le désirez, les informations obtenues durant l’étude auprès des 
autres participants et vous seront agrégées puis envoyées à votre organisation. 
 
Votre participation est importante. Toutefois, elle est complètement volontaire et vous n’êtes pas tenu de compléter le questionnaire. 
Vous pouvez également refuser de répondre aux questions individuelles et vous pouvez vous retirer de l’étude à tout moment. Si vous 
avez des préoccupations concernant ce projet de recherche n’hésitez pas à contacter le chercheur principal (Jason Perepelkin) par 
courriel (jason.perepelkin@usask.ca), par téléphone (306-966-6992), ou par télécopieur (306-966-6377). 
 
Sincèrement,  
 
     
Grant Wilson, BComm 
Candidat à la MSc 
Université de Saskatchewan 
 
 Jason Perepelkin, PhD 
Professeur adjoint 
Université de Saskatchewan 
 
 Marc-Antoine Vachon, candidat au PhD 
Professeur  
Département de marketing  
ESG-UQAM 
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June 25, 2012 
 
«Title»«First_Name»«Last_Name» 
«Company» 
«Address» 
«City», «Province»  «Postal_Code» 
 
RE: Business Practices of Canadian Biotechnology Companies 
 
Dear «Title»«Last_Name», 
 
You recently received a request to complete a questionnaire regarding your company’s current 
business practices.  If you have already completed the questionnaire online or have already 
returned it via mail, thank you.  If you have not yet completed the questionnaire and intend to do 
so, we would ask that you complete it as soon as possible and return it in the pre-stamped 
envelope provided or visit https://survey.qualtrics.com/SE/?SID=SV_5hFkveDPwEF0HxW and 
enter your identification code («CODE»).  Your participation is important and we look forward to 
receiving your completed questionnaire. 
 
As you know, the purpose of this study is to understand the current business practices of 
Canadian biotechnology companies.  As a token of our appreciation for your participation, if you 
would like, the information obtained from you and other participants in the study will be 
aggregated and sent to your organization. 
 
Should you have any concerns about this research project do not hesitate to contact the principal 
investigator (Jason Perepelkin) by e-mail (jason.perepelkin@usask.ca), phone (306-966-6992), or 
facsimile (306-966-6377).  You completing this questionnaire, either by mail or online, 
constitutes consent for the researchers to use the data for the purpose of conducting the study, as 
this study has received exempt status from the University of Saskatchewan Behavioural Research 
Ethics Board (BEH 120-104, April 9, 2012).  Should you have any questions regarding your 
rights as a participant in this study you may call the Ethics Office at the University of 
Saskatchewan (306-966-2084).  Out of town participants may call collect. 
 
Sincerely, 
 
     
Grant Wilson, BComm 
MSc Candidate 
University of Saskatchewan 
 
 Jason Perepelkin, PhD 
Assistant Professor 
University of Saskatchewan 
 Marc-Antoine Vachon, PhD Candidate 
Professor, Department of Marketing 
ESG-UQAM 
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25 juin 2012 
 
«Title»«First_Name»«Last_Name» 
«Company» 
«Address» 
«City», «Province»  «Postal_Code» 
 
Objet: Les pratiques commerciales des entreprises canadiennes en biotechnologie 
 
Bonjour «Title»«Last_Name», 
 
Vous avez récemment reçu une demande pour répondre à un questionnaire concernant les pratiques 
commerciales actuelles de votre entreprise. Si vous avez déjà rempli le questionnaire en ligne ou l’avez 
déjà acheminé par la poste, merci. Si vous n’avez pas rempli le questionnaire mais vous avez l’intention de 
le faire, nous vous demanderions de le remplir le plus tôt possible et de le retourner avec l’enveloppe 
préaffranchie, ou d’accéder au https://survey.qualtrics.com/SE/?SID=SV_1YeyyTUzqDZ9FYw et d’entrer 
votre code d’identification («CODE»). Votre participation est importante et nous espérons fortement 
recevoir votre questionnaire rempli.   
 
Comme vous le savez, l’objectif de cette étude est de comprendre quelles sont les pratiques commerciales 
actuelles des entreprises canadiennes en biotechnologie. En gage de notre appréciation, si vous le désirez, 
les informations obtenues durant l’étude auprès des autres participants et vous seront agrégées puis 
envoyées à votre organisation. 
 
Si vous avez des préoccupations concernant ce projet de recherche, n’hésitez pas à contacter le chercheur 
principal (Jason Perepelkin) par courriel (jason.perepelkin@usask.ca), par téléphone (306-966-6992), ou 
par télécopieur (306-966-6377). En remplissant ce questionnaire, par courrier ou en ligne, vous donnez 
votre consentement aux chercheurs pour qu’ils utilisent les données dans le but de conduire l’étude, tel 
qu’approuvé par le comité sur l’éthique en recherche comportementale de l’Université de Saskatchewan 
(BEH 120-104, 9 avril 2012). Si vous avez des questions quant à vos droits comme participant à cette 
étude, vous pouvez appeler le Bureau de l'éthique à l'Université de Saskatchewan (306-966-2084). Les 
participants hors région peuvent effectuer des appels à frais virés.  
 
Sincèrement, 
 
     
Grant Wilson, BComm 
Candidat à la MSc 
Université de Saskatchewan 
 
 Jason Perepelkin, PhD 
Professeur adjoint 
Université de Saskatchewan 
 
 Marc-Antoine Vachon, candidat au PhD 
Professeur  
Département de marketing  
ESG-UQAM 
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